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INTRODUCTION, AIM AND 






Lipids are water-insoluble molecules with a diversity of biological roles. Lipids are 
indispensible in eukaryotic cells for cell membrane structure and function, as a source 
of energy, and as ligands of specific transcription factors. Their various functions can 
be illustrated by the biological significance of one well known lipid; cholesterol. Cho-
lesterol is a structural component of plasma and organelle membranes (1). Cholester-
ol is the precursor for biologically important molecules such as steroid hormones and 
bile acids. Additionally, cholesterol activates Sonic Hedgehog (2), a signalling protein 
which is essential for embryonic development. The importance of cholesterol for 
normal development is emphasized by the devastating effects of inborn errors in cho-
lesterol synthesis, such as the Smith-Lemli-Opitz syndrome (3). On the other hand, 
elevated plasma concentrations of cholesterol, particularly low-density lipoprotein 
cholesterol (LDL-c) is a well known risk factor in the development of cardiovascular 
disease, similar to increased plasma concentrations of another lipid, triglycerides, (4). 
As both shortage and excess of lipids disrupt normal growth and development, lipid 
metabolism needs to be carefully balanced. 
METABOLIC PROGRAMMING
Environmental factors during gestation, such as nutrional conditions, have been relat-
ed to the susceptibility to chronic diseases later in life. A U-shaped relationship exists 
between birth weight and increased susceptibility to develop adult disease, as both 
fetal undernutrition and fetal overnutrition increase the risk to develop features of the 
metabolic syndrome. Epidemiological studies showed associations between impaired 
fetal nutrition and an increased vulnerability to develop components of the metabolic 
syndrome such as hypertension, diabetes, cardiovascular disease and obesity (5-15). 
In addition, epidemiological studies showed a similar inverse relationship between 
size at birth, as a marker of impaired fetal nutrition, and dyslipidemia in adulthood. 
Dyslipidemia is strongly related to atherosclerosis, obesity, diabetes and fatty liver 
disease (16, 17). A small abdominal circumference at birth is associated with raised 
serum concentrations of total and low-density lipoprotein cholesterol (LDL-c) and 
(the LDL-c associated) apolipoprotein B at the age of about fifty years (5). People ex-
posed to famine in early gestation, due to the Dutch hunger winter in 1944, display 
a more atherogenic lipid profile when compared to people that were not exposed to 
famine in their fetal period (18). The Hertfordshire study in which a cohort of men 
and woman born between 1911 and 1930 in England was studied in their sixties, 
showed that reduced fetal growth (reflected by birth weight) was associated with 
higher plasma triglyceride levels and lower high-density lipoprotein levels in adult-
hood (7). Already shortly after birth, infants that are small-for-gestational age (SGA) 
display a more atherogenic plasma lipid profile (higher total cholesterol, triglycerides 
and LDL-c) compared with normal weight controls (19). Additionally, SGA newborn 
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infants displayed significant maximum aortic thickening with hypertriglyceridemia 
compared with normal weight controls suggesting that fetal nutrition might predis-
pose to increased risk of later cardiovascular disease (20). 
The epidemiological association between fetal environment and/or size at birth and 
adult disease has lead to several hypotheses on the developmental origins of health and 
disease. The term “Programming” was first defined by Lucas, as reflecting the scenario 
by which a stimulus or insult operating at a critical or sensitive period of growth and 
development results in long term consequences for the structure or function of the 
organism. The important underlying idea is that the programming event can only 
occur during a specific window of sensitivity (21, 22). Hales and Barker described 
the “thrifty phenotype” hypothesis which suggests that fetal adaptations in answer 
to a nutritionally deprived environment may permanently reset or program fetal 
metabolism in order to optimize its chances of survival in what it expects to be a poor 
nutritional environment. This adaptive response is beneficial for the organism when 
placed in a nutrional poor fetal environment but becomes harmful in a nutritional 
rich postnatal environment (21). Epidemiological studies have also related postnatal 
nutrition (human milk versus formula) to the susceptibility in the development of 
cardiovascular disease, hypertension (23, 24) and dyslipidemia (14, 25). Although 
the epidemiological relationships between early events and adult disease have become 
convincingly strong, the biological mechanisms behind these programming effects 
have remained largely unclear. To gain insight in the mechanisms behind metabolic 
programming would allow for the development of preventive strategies to target the 
negative long-term consequences of early nutrition.
METABOLIC PROGRAMMING AND 
ANIMAL MODELS 
To unravel the pathophysiological mechanisms behind fetal programming, a variety 
of animal models implying food restriction or the manipulation of specific nutrients 
during gestation has been developed (26, 27). An increasing number of experimental 
studies using different strategies in a variety of animal species demonstrated fetal pro-
gramming effects (26, 27). An established model used in rat and mice to investigate 
the mechanisms behind programming effects, consists of maternal protein restriction 
during gestation. Studies in rodents show that maternal protein restriction during 
gestation leads to features of the metabolic syndrome in the adult offspring, such as 
obesity, hypertension and diabetes (28-34). As stated before, the pathophysiological 
mechanisms behind metabolic programming are largely unknown. One proposed 
mechanism is that of epigenetic modification. This hypothesis implies that early life 
environmental conditions can cause stable alterations in gene expression potential 
that persist throughout life, without modifying DNA sequence. For example; adult in-
dividuals that were prenatally exposed to famine during the Dutch Hunger Winter in 
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1944-45 had less DNA methylation of the IGF2 gene (insulin-like growth factor, a key 
factor in human growth and development) compared to their unexposed same-sex 
siblings (35). Additionally, rodent studies have shown that protein restriction during 
gestation induces epigenetic modification of genes involved in lipid and carbohydrate 
metabolism in the offspring (36, 37). We aimed to increase the mechanistic under-
standing of metabolic programming, in order to eventually allow for the targeted 
prevention of long-term health consequences of early environmental conditions. We 
determined in an established experimental model the effect of a low protein diet dur-
ing gestation on maternal-fetal cholesterol transport and on fetal lipid synthesis in 
mice. To set the context of our studies, we first provide a concise overview addressing 
cholesterol and lipid metabolism in the fetal, neonatal and adult period. 
CHOLESTEROL SyNTHESIS 
In mammals, cholesterol originates from either de novo synthesis or from exogenous 
sources (i.e. dietary absorption or placental transfer). All nucleated mammalian cells 
can synthesize cholesterol from acetyl-CoA via the mevalonate enzymatic pathway. 
The liver and intestine are considered major sites of cholesterol synthesis in the adult 
situation (38). The first step of cholesterol biosynthesis is the formation of 3-hydroxy-
3-methylglutaryl-CoA (HMG-CoA) from acetyl-CoA and acetoacetyl-CoA, catalyzed 
by the enzyme HMG-CoA synthase. HMG-CoA is then converted to mevalonate by 
HMG-CoA-reductase, which under physiological conditions represents the rate-con-
trolling step. Mevalonate is converted to isopentenyl-5-pyrophosphate, condensated 
to squalene and further metabolized to lanosterol. Conversion of lanosterol into cho-
lesterol takes another 19 enzymatic reactions. In adult humans, the daily synthesis of 
cholesterol amounts to approximately 10 mg/kg body weight. Synthesis inversely 
adapts to the dietary intake, i.e. synthesis increases when intake is low and vice versa. 
Cholesterol is transported in the circulation in lipoproteins: chylomicrons, very-low-
density lipoproteins (VLDL), high-density lipoproteins (HDL) and low-density lipo-
proteins (LDL). The body can dispose itself from excess cholesterol via fecal excretion, 
either as cholesterol or after hepatic metabolism, as bile acids. 
REGULATION OF CHOLESTEROL 
METABOLISM
Refined mechanisms exist to maintain cholesterol balance in different metabolic cir-
cumstances. The liver-X-receptors (LXRs) are key players in the regulation of choles-
terol homeostasis. LXRs are ligand-activated transcription factors that belong to the 
nuclear receptor superfamily (39). There are two LXR isoforms; LXRα (NR1H3) and 
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LXRβ (NR1H2) that regulate gene expression via direct binding to DNA response 
elements in promoter regions of their target genes. LXRα is mainly expressed in 
liver, intestine and adipose tissue whereas LXRβ is more ubiquitously expressed (40). 
Apart from their endogenous ligands which are oxysterols (oxidized cholesterol de-
rivatives) synthetic LXR agonists such as T0901317 have been developed (41). In 
the absence of ligands, LXR and its obligate heterodimer Retinoid X Receptor (RXR) 
are bound to LXR response elements (LXRe) in complex with corepressors in the 
promoter sites of their target genes. Upon ligand induced activation, the corepressor 
complexes are exchanges for coactivators after which gene expression of the target 
genes takes place (fig. 1). Both LXR isoforms bind to their obligate heterodimer Retin-
oid X Receptor (RXR) after which they bind to LXR response elements (LXRe) in the 
promoter sites of their target genes, thereby regulating gene expression. LXR serves as 
a cholesterol sensor: when cellular oxysterols accumulate due to increased cholesterol 
concentration, LXR generates the transcription of genes that induce efflux from cho-
lesterol out of the cell. Significant LXR target genes are members of the family of ATP-
binding cassette (ABC) transporters. Upon LXR activation, ABC transporters, encod-
ing for proteins involved in cellular cholesterol efflux to bile or the intestinal lumen 
(ABCG5, ABCG8), to high-density lipoproteins (HDL) (ABCA1, ABCG1) are activated 
(see figure 2). Additionally, activation of LXR leads to induction of the conversion 















Figure 1. in the nucleus, rXr and lXr associate as heterodimers and are bound to lXres in the 
promotor regions of target genes in complex with co-repressors. in the absence of ligands, they repress 
target gene transcripticon. after ligand activation (with oxysterols or t0901317) a conformational 
change in the receptor takes place after which the co-repressors are dissociated and the co-activators 
are recruited to initiate gene transcription.  
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bile acid synthesis), subsequently generating efflux from cholesterol out of the cell. 
LXR activation results in an increased plasma HDL-cholesterol, decreased intestinal 
cholesterol absorption, increased hepatobiliary cholesterol secretion and increased 
fecal neutral sterol excretion; please see for review (42). In addition to cholesterol ef-
flux, LXR activation induces expression of genes involved in de novo lipogenesis; sterol 
regulatory element binding protein 1c (SREBP1c), acetyl CoA carboxylase (ACC), 
fatty acid synthase (FASN) and stearoyl-Coenzyme A desaturase 1 (SCD1) (43). Both 
isoforms of LXR are expressed in the murine and human placenta (44), and LXR has 
been postulated to have a crucial role in fetal cholesterol metabolism (45). 
hepatocyte










cholesterol to fecal 
bile
Figure 2.
Figure 2. Upon lXr activation, lXr target genes expression is induced. lXr induces hepatic abca1 
expression leading to the efflux of cholesterol to Hdl. lXr induced the hepatic expression of both 
heterodimers abcG5 and abcG8 leading to cholesterol secretion into bile. Furthermore, lXr 
activation induces expression of srebp1c resulting in fatty acid synthesis. lXr activation results in 
upregulation of cYp7a1, resulting in bile acid synthesis. this is not a complete list of target genes.    
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FETAL CHOLESTEROL AND 
TRIGLyCERIDE METABOLISM 
The significance of cholesterol for the organism is best illustrated early in life. During 
the rapid growth of the fetal period, significant amounts of cholesterol are required 
for proper growth and embryological development. Defects in cholesterol synthesis 
have detrimental consequences for the individual. In humans, the Smith-Lemli-Opitz 
syndrome, desmosterolosis and mevalonic aciduria are well described examples of 
inborn errors in cholesterol synthesis leading to serious malformations in various 
organ systems (46). Unlike the adult situation in which cholesterol metabolism is in 
steady state, the fetus, due to its rapid growth and development, accumulates choles-
terol (47). Placental steroid hormone synthesis and the rapidly growing fetus render 
gestation a high cholesterol demanding state. Both placental (48), and fetal tissues are 
capable of de novo cholesterol synthesis (49). Compared to adult synthesis rates, fetal 
sterol synthesis rates are much higher (50). Besides de novo synthesis, several lines of 
evidence support the concept that maternal cholesterol (via placental transport) con-
tributes to fetal cholesterol accretion. First, maternal hypercholesterolemia strongly 
correlates with the formation of aortic fatty streaks in the human fetus (51). Second, 
in the Dhcr7-/- mouse, a model of the Smith-Lemli-Opitz syndrome which is unable 
to synthesize cholesterol, the presence of cholesterol was demonstrated in the fetus 
indicating that exogenous cholesterol must have been transported to the fetus (52). 
Third, transfer of labeled cholesterol ([3,4-13C
2
]-cholesterol) from mother to fetus 
was described in mice, indicating that cholesterol from the maternal circulation is 
transported to the fetus (53). Finally, synthetic activation of LXR during gestation 
increased the expression of ABCA1 and ABCG1 in the murine placenta followed by a 
functional increase of maternal-fetal cholesterol transport measured using 14C labeled 
cholesterol (54). 
Triglycerides represent the storage and transport form of lipids and are composed of a 
glycerol back bone connected to three fatty acid molecules. In parallel to cholesterol, 
fatty acids can be taken up from the diet or can be synthesized by the body itself in 
the liver: de novo lipogenesis. Although in adults on a western-type diet, hepatic de novo 
lipogenesis is a quantitatively minor pathway as was shown by Hellerstein et al (55), 
biosynthesis of fatty acids might be a relevant compensatory pathway in the growth 
restricted fetus. In the present project, we addressed the effects of different fetal nu-
tritional conditions on fetal lipid metabolism and on maternal-fetal lipid transport. 
In a mouse model, we determined the effects of synthetic activation of LXR during 
gestation on fetal lipid metabolism in mice. In growth restricted premature human 
newborns, we determined the influence of fetal growth restriction on the biosynthe-




Comparable to fetal nutrition, the composition of early postnatal nutrition can exert 
effects on adult health. Human milk contains a substantial larger amount of choles-
terol (≈ 2-4 mmol/l) than cow’s milk based formulas (0.3-0.8 mmol/l) (56, 57). 
Breastfeeding has been associated with a decreased epidemiological risk to develop 
cardiovascular disease and obesity, and it is linked to a protective lipid profile when 
compared to formula feeding (25, 58). Higher dietary cholesterol intake is inversely 
related to endogenous or de novo cholesterol synthesis in infants. It has been hypoth-
esized that the inverse relationship between the intake of human milk and the de novo 
cholesterol synthesis could lead to smaller central cholesterol pools thereby poten-
tially reducing cardiovascular disease risk (14, 26, 56, 59). In addition to higher cho-
lesterol content, human milk differs from formulas in other qualities, including the 
composition and concentration of oligosaccharides. Oligosaccharides have become 
under scientific attention, because of demonstrated and presumed beneficial prebiotic 
effects (60-62).
PREBIOTICS AND BILE ACID 
METABOLISM 
Prebiotics are defined as non-digestible food ingredients that beneficially affect the 
host by selectively stimulating growth and/or activity of one or a limited number of 
bacteria (bifidobacteria, lactobacilli) in the colon (63). Oligosaccharides are a major 
constituent of human milk. Infants fed human milk have a larger proportion of bifi-
dobacteria and lactobacilli in their intestinal bacterial flora compared with formula 
fed infants (64, 65) It is well known that colonic bacterial species can metabolize bile 
acids present in the intestinal lumen, for example by deconjugation and dehydroxy-
lation. Microbial bile acid metabolism can thus affect bile acid metabolism. Compa-
rable to inborn errors in cholesterol synthesis, several defects in bile acid synthesis 
with devastating consequences have been described, underscoring the relevance of 
bile acid metabolism (66). Bile acids have several important functions in addition 
to facilitating the absorption of dietary fat and the fat-soluble vitamins A, D, E and 
K. Firstly, the secretion of bile acids from hepatocytes into the biliary system is the 
main driving force for bile formation (67). Secondly, bile acids are essential in cho-
lesterol homeostasis as conversion of cholesterol into bile acids and their subsequent 
fecal loss provides the major route for removal of excess cholesterol from the body. 
Interestingly, Infants fed human milk have a larger bile acid pool size and a more ef-
ficient fat absorption compared to formula fed infants (68). It has remained unclear, 
however, whether these observations are related to prebiotic effects of human milk 
constituents. 
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BILE ACID SyNTHESIS 
Bile acids are synthesized from cholesterol, exclusively in the liver. The enzymatic 
conversion of cholesterol can occur via two main pathways. In the neutral or classi-
cal pathway, the steroid nucleus is modified by hydroxylation reactions prior to the 
side-chain shortening. Cholesterol 7α-hydroxylase (CYP7A1) catalyzes conversion of 
cholesterol into 7α-hydroxycholesterol. This step is considered to be rate-controlling 
in bile acid synthesis and is subject to negative feedback of enterohepatic cycling 
of bile acids. In the acidic pathway, the first step involves 27-hydroxylation of the 
cholesterol side-chain (to yield 27-hydroxycholesterol), catalyzed by the enzyme 
sterol-27-hydroxylase (CYP27A1). Finally, C27-3β-steroid dehydrogenase converts 
the 7α-hydroxycholesterol formed via either pathway into the two primary bile ac-
ids: cholate (CA) and chenodeoxycholate (CDCA). Under physiological conditions, 
bile acids are conjugated with glycine or taurine and secreted via the bile in the in-
testinal lumen, where they facilitate the uptake of dietary fat and other hydrophobic 
compounds. The majority of bile acids is reabsorbed from the ileum mediated by the 
apical sodium bile salt transporter (ASBT) (69) after which transport via the portal 
system back to the liver and uptake by hepatocytes completes the enterohepatic cir-
culation of bile acids. A small fraction of the bile salts escapes ileal reabsorption and 
enters the colon, where they are deconjugated and subsequently dehydroxylated by 
intestinal bacteria resulting in the so-called secondary bile acids (deoxycholate and 
lithocholate) and tertiary bile acids (ursodeoxycholate). These unconjugated bile salts 
can be passively reabsorbed from the colon, which results in the presence of the sub-
sequent secondary and tertiary bile acids in the enterohepatic circulation.
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AIM AND OUTLINE OF THE THESIS 
Lipids and bile acids are indispensable for various physiological functions in mam-
mals and their adequate intake or biosynthesis is thus essential for normal devel-
opment. Genetic inability to synthesize cholesterol during the fetal period leads to 
severe congenital malformations. The relevance of adequate bile acid and/or choles-
terol synthesis is emphasized by the profound health consequences of inborn errors 
in bile acid and cholesterol synthesis as reviewed in chapter 2. Lipids are of crucial 
importance for all cells in human body as a structural component for cell membranes. 
On the other hand, excess amounts of cholesterol and/or triglycerides contribute to 
an increased risk for the development of cardiovascular diseases, clarifying the im-
portance of a carefully balanced regulation of lipid metabolism. Human and animal 
studies indicate that maternal nutrition during pregnancy and the type and duration 
of nutrition after birth affect short-term and long-term (adult) lipid metabolism. The 
mechanisms underlying these lasting effects of pre- and early postnatal events are 
largely unknown. We aimed to characterize and unravel the role of specific dietary 
and pharmacological interventions during prenatal and early postnatal life on 
physiologically relevant parameters of lipid and bile acid metabolism. First, we 
determined the effect of a low protein diet during gestation on cholesterol transport 
from mother to fetus and on fetal cholesterol and fatty acid synthesis in mice. A low 
protein diet during gestation is an established model to study metabolic consequenc-
es of maternal under-nutrition during gestation. We provided mice with a protein 
deficient diet (9% casein instead of 18 % casein) during pregnancy and determined 
relevant lipid fluxes using stable isotopes (chapter 3). Previous research shows that 
fetal hepatic expression levels of genes involved in lipid metabolism are lowered af-
ter maternal protein restriction during gestation (37). We tested if this alteration 
in mRNA expression levels was translated into quantitative changes in physiological 
relevant lipid fluxes. 
Infants born prematurely, may constitute a human model of the last trimester of ges-
tation in which the impact of environmental factors can be studied, Chapter 4 deals 
with the de novo lipogenesis and cholesterogenesis in preterm human infants in the 
first days after birth. Two questions were attended to. First, does fetal undernutrition, 
as reflected by a birth weight below the tenth percentile for gestational age influence 
the rate of de novo cholesterol synthesis? Second, does intrauterine growth restriction 
enhance de novo lipogenesis, for example, as a compensatory mechanism? 
The nuclear receptor LXR, a key player in the regulation of cholesterol and in the 
synthesis of lipids, is suggested to be involved in maternal-fetal cholesterol transport. 
Theoretically, manipulation of LXR during gestation could affect fetal lipid metabo-
lism. Pharmacological interventions in the fetal environment may induce long-term 
programming effects. In chapter 5 we describe both acute and long-term effects of 
pharmacological LXR activation during gestation on lipid metabolism in the fetal and 
adult offspring in mice. 
Infants fed human milk have a larger bile acid pool and a more efficient fat absorption 
than infants fed artificially cow’s milk formula. Unlike ‘classic’ formula feeding, 
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human milk contains natural oligosaccharides, and infants fed human milk have a 
lager proportion of bifidobacteria and lactobacilli in their intestinal bacterial flora 
compared to formula fed infants. Colonic bacteria can metabolize bile acids present 
in the intestinal lumen. In chapter 6 we tested if oligosaccharides comparable to 
those present in human milk increase the bile acid pool size. We described the effect 
of alteration of the colonic bacterial flora, mimicking the bacterial flora of infants fed 
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There is a multitude of cholesterol and bile acid synthesis defects. Their frequency is 
relatively rare, and individual diseases frequently require different approaches. This 
chapter provides an overview of the most relevant defects in cholesterol and bile acid 
biosynthesis and their presentation, and diagnostic and therapeutic approaches. 
CHOLESTEROL METABOLISM
Cholesterol is essential for eukaryotic cells as a structural component of plasma and 
organelle membranes. Cholesterol is also the precursor for biologically important 
compounds such as steroid hormones and bile acids. Additionally, cholesterol acti-
vates Sonic Hedgehog (1), a signalling protein essential for normal embryonic de-
velopment. Cholesterol is derived from the diet, but can also be synthesized de novo. 
Particularly during rapid fetal growth, significant amounts of cholesterol are required, 
which can be derived from the mother via placental supply, or via fetal or placental 
synthesis. Cholesterol is synthesized by all nucleated mammalian cells. Biosynthe-
sis occurs from acetyl-CoA via the mevalonate pathway in which several enzymatic 
steps are involved (Figure 1 shows a simplified scheme of the pathway). The first 
step is the formation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) from acetyl-
CoA and acetoacetyl-CoA, catalyzed by the enzyme HMG-CoA synthase. HMG-CoA 
is then converted to mevalonate by HMG-CoA-reductase, which represents the rate-
controlling step. Mevalonate is converted to isopentenyl-5-pyrophosphate, conden-
sated to squalene and further metabolized to lanosterol. Conversion of lanosterol into 
cholesterol takes another 19 enzymatic reactions. The importance of the cholesterol 
synthesis pathway is evident from the profound effects of several inborn errors in 
cholesterol synthesis. As most inborn errors in cholesterol synthesis are very rare, 
evidence for the treatment of these inborn errors is limited. 
Bile acid metabolism
Bile acids are synthesized from cholesterol in the liver exclusively. The enzymatic 
conversion of cholesterol can occur via two pathways (Fig. 2). In the neutral or 
classical pathway, the steroid nucleus is modified by hydroxylation reactions prior to 
the side-chain shortening. Cholesterol 7α-hydroxylase (CYP7A1) catalyzes conversion 
of cholesterol into 7α-hydroxycholesterol. This step is considered to be rate-controlling 
in bile acid synthesis. In the acidic pathway, the first step involves 27-hydroxylation 
of the cholesterol side-chain (to yield 27-hydroxycholesterol), catalyzed by the 
enzyme sterol-27-hydroxylase (CYP27A1). Finally, C27-3α-steroid dehydrogenase 
converts the 7α-hydroxycholesterol formed via either pathway into the two primary 
bile acids: cholic acid (CA) and chenodeoxycholic acid (CDCA). After their synthesis, 
primary bile acids are conjugated with glycine or taurine and secreted via the bile 
into the intestinal lumen, where they facilitate the uptake of dietary fat and other 
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Figure 1. simplified scheme of the cholesterol biosynthesis pathway. the described inborn errors 
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Figure 2Figure 2. pathway for the biosynthesis of the primary bile acids. inborn errors of bile acid synthesis 
are depicted in bold. cYp7a1, cholesterol 7α-hydroxylase; cYp27a1, sterol 27-hydroxylase; 
cYp7b1, oxysterol 7α-hydroxylase; 3β-Hsd, 3β-hydroxy-∆5-c27-steroid dehydrogenase; cYp8b1, 
sterol 12-alpha-hydroxylase; aKr1d1, 5βrd: 3-oxo-∆4-steroid 5β-reductase; cH25H, cholesterol 
25-hydroxylase. Adapted from Lefebvre P et al. Role of bile acids and bile Acid receptors in metabolic 
regulation. Physiol Rev. 2009; 89(1):147-91, Thomas C et al.Targeting bile-acid signalling for metabolic 
diseases. Nat Rev Drug Discov. 2008;7(8):678-93. Liver disease in Children,3rd edition ,Edited by FJ 
Suchy RJ Sokol WF. Balistreri, Book chapter 31, Setchell KDR
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hydrophobic compounds. The majority of bile acids are reabsorbed in the ileum, 
transported via the portal system back to the liver to complete the enterohepatic 
circulation. A small fraction of the bile salts escapes ileal reabsorption and enters the 
colon, where they are deconjugated and subsequently dehydroxylated by intestinal 
bacteria. These unconjugated bile salts can be passively reabsorbed from the colon, 
which results in the presence of so-called secondary and tertiary bile acids in the 
enterohepatic circulation (Fig. 3). Bile acids have several important functions in 
addition to facilitating the absorption of dietary fat and fat-soluble vitamins. The 
secretion of bile acids from hepatocytes into the biliary system drives bile formation. 
Bile acids are essential in cholesterol homeostasis; conversion of cholesterol into bile 
acids and their subsequent fecal loss provides the major route for removal of excess 














Figure 3. enterohepatic circulation of bile acids. bile acids are synthesized from cholesterol in the 
liver. after synthesis, primary bile acids are conjugated to with glycine or taurine and secreted into 
the intestinal lumen. the majority of bile acids is reabsorbed in the ileum and transported back 
to the liver via the portal system. some bile acids enter the colon where they are deconjugated 
and dehydroxylated by the intestinal bacterial flora. these secondary and tertiary bile acids can 
be passively absorbed from the colon and are transported back to the liver via the enterohepatic 
circulation. the fecal excretion of bile is a route for removal of excess cholesterol from the body. 
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INBORN ERRORS OF CHOLESTEROL BIOSyNTHESIS 
Mevalonic aciduria (Ma) and hyperIgD and periodic fever syndrome (hIDS)
MA and HIDS are disorders caused by deficiency of mevalonate kinase (MVK). MA 
is a severe and often fatal disease presenting with a variety of symptoms (dysmor-
phic features, cataracts, hypotonia, developmental delay, ataxia and cerebellar atrophy, 
failure to thrive, recurrent febrile illnesses with enteropathy, hepatosplenomegaly, 
lymphadenopathy, arthralgia, oedema and rashes) (2). HIDS is a less severe condition, 
characterized by recurrent fever episodes associated with lymphadenopathy, arthral-
gia, gastrointestinal problems and rash, but without neurological symptoms or dys-
morphic features (3). MA and HIDS are rare diseases with about 30 and 180 patients 
respectively described worldwide (4). Since identification of the affected gene in 
1992 (5), several disease causing mutations have been reported. Diagnosis is based on 
detection of elevated levels of mevalonic acid in urine or plasma. In HIDS, however, 
this may not always be conclusive. MVK activity is usually below detection levels in 
MA patients, whereas some residual MVK activity is present in HIDS. Plasma levels of 
cholesterol are usually in the lower range of normal (6). In HIDS, serum IgD and IgA 
are frequently elevated. The diagnosis of MA and HIDS is confirmed by demonstrating 
mutations in the gene. The pathogenesis of both diseases is still unclear, either accu-
mulation of mevalonic acid or deficiency of cholesterol and intermediates have been 
postulated to play a role.
Several attempted therapeutic strategies have not been successful in treating MA. Oral 
cholesterol supplementation worsened diarrhoea (6). Antioxidant treatment with 
ubiquinone combined with vitamin C and E to treat a postulated increased sensitivity 
to reactive oxygen stress, appeared to stabilize clinical symptoms in a few patients (7). 
However, a combination of cholesterol, ursodeoxycholic acid (UDCA), ubiquinone and 
vitamin E did not lead to clinical improvement (6). Treatment in 2 patients with lovastatin 
to block mevalonic acid production resulted in the development of severe clinical crisis 
(hyperthermia, vomiting, diarrhoea and marked elevation of serum creatinin kinase 
levels) (6). Intervention with prednisone (2 mg/kg/d) was effective during clinical 
crisis in 2 patients (6). One MA patient with associated nephritis was successfully 
treated with anakinra (an interleukin-I-receptor antagonist) (8). Remission (during a 
15-month follow-up period) of febrile attacks and inflammation after allogenic bone 
marrow transplantation was described in a three year old patient (9). 
The prognosis of HIDS is benign with complications (amyloidosis) being rare. 
Various pharmacological agents have been tried in the treatment of febrile episodes 
and associated symptoms in HIDS. Anti-inflammatory drugs (colchicine, thalidomide, 
cyclosporine and intravenous immunoglobulin) did not consistently suppress or 
shorten febrile episodes (3, 10, 11). Individual patients responded to prednisone 
(3, 10) or non-steroidal anti-inflammatory drugs (NSAIDs) (12). A randomized, 
double blind, crossover study with simvastatin in 6 patients, did not significantly 
affect duration or frequency of febrile illnesses (13). As plasma levels of TNFα and 
interleukin (IL)-1β are elevated during febrile attacks, anticytokine therapy has been 
attempted. Case reports described a limited effect of antitumor necrosis factor (TNF) 
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treatment with etanercept (14,15). Anakinra shortened frequency and duration 
of febrile attacks in sporadic cases (3,15). Studies have been performed in small, 
heterogeneous groups and sofar; there is no consensus on treatment of HIDS.
Concluding, for patients with MA, intervention with prednisone or with anakinra may 
be successful (III/C). The use of statins is not recommended in MA patients (III/C). 
In the treatment of HIDS, thalidomide (II/B), cholchicine (II/B) and statins (I/B) are 
not recommended whereas symptomatic treatment of fever and pain with prednisone 
or with NSAIDs may be successful (II/C). Anticytokine therapy with etanercept or 
anakinra may be successful in HIDS patients (III/C).
Smith-Lemli-Opitz syndrome (SLOS)
SLOS was first described in 1964 as an autosomal recessive malformation syndrome 
with microcephaly, dysmorphic facial features, genital abnormalities, limb defects 
and mental retardation (16). Decades later, the underlying biochemical cause was 
identified (17). Deficiency of 7-dehydrocholesterol-∆7 reductase (7-DHCR) impairs 
normal cholesterol synthesis leading to hypocholesterolemia and accumulation of 
the precursors 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC). 
The gene DHCR7, defective in SLOS, was identified in 1998 (18) and since then 
over 100 different mutations have been reported. SLOS is characterized by a broad 
spectrum of malformations in various organ systems (reviewed in (19). Its incidence 
is estimated between 1:20.000 - 1:70.000 births (19) The disruption of normal 
development and growth is classically attributed to the deficiency of cholesterol 
or to the accumulation and deposition of the (potentially toxic) precursors. SLOS 
is diagnosed by the determination of elevated concentrations of 7DHC and 8DHC 
in plasma. DHC7 mutation analysis can be performed to confirm the diagnosis. 
Cholesterol concentrations in plasma are low or normal (19). Prenatal diagnosis can 
be performed by measuring elevated levels of 7-DHC concentrations in amniotic fluid 
or chorionic villus biopsies (20). 
No pharmacological strategy has been proven effective in curing SLOS. Dietary sup-
plementation with cholesterol seems a logical treatment because it could be expected 
to increase plasma and tissue cholesterol levels and to down-regulate its synthesis and 
the levels of, potentially toxic, precursors. Unfortunately, because brain cholesterol in 
mammals is dependent on de novo synthesis and plasma cholesterol does not efficiently 
cross the blood brain barrier, the effect of cholesterol supplementation on brain func-
tion is expected to be limited. Furthermore, prior developmental defects cannot be re-
versed by cholesterol treatment. Cholesterol supplementation (administered as natu-
ral products such as egg yolk, meat based formulas and liver or crystalline cholesterol 
in oil or aqueous suspension) has been evaluated in several trials. Doses of cholesterol 
used ranged between about 20-150 mg/kg/d (21-23). Cholesterol supplementation 
improved the serum ratio of cholesterol to total sterols and decreased the level of 
7DHC (24). Some observational studies show improvement in growth, behaviour, 
gastrointestinal symptoms and photosensitivity (21-23). However, these studies were 
conducted in small and heterogeneous patient groups and the described improve-
ments have not been correlated to the biochemical changes. Cholesterol treatment 
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Table 1. Features of inborn errors in cholesterol biosynthesis. (a) reviewed in porter F et al. human 
malformation syndromes due to inborn errors of cholesterol synthesis. curr opin pediatr 2003 
dec;15(6):607-13. 
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ol  in tissue
Inheritence
 
autosomal recessive autosomal recessive autosomal recessive suggested autosomal 
recessive
X-linked dominant X-linked dominant autosomal recessive
Prevalence ± 30 cases ± 180 cases 1:20.000-70.000 2 cases ± 100 cases ± 30 cases ± 10 cases
Animal 
model
mvk +/- mouse dhcr7 -/- mouse (a) dHcr24 -/- mouse (a) tattered (td) mouse (a) bare patches (bpa) and striated  
(str) mouse (a)
ichthyosis mouse (a)
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does not influence the developmental progress in children and adults with SLOS (24). 
Bile acids including CDCA and UDCA added to cholesterol treatment in some studies 
did not provide benefit in treatment (22, 23). Treatment of SLOS with simvastatin, an 
inhibitor of cholesterol synthesis resulted in inconclusive effects. Adverse effects in 
two patients are reported (25), whereas simvastatin treatment in two other patients 
was well tolerated and lowered plasma 7DHC and 8DHC. In these patients, improve-
ment of anthropometric measurements was suggested (26). Haas et al compared cho-
lesterol monotherapy with cholesterol and simvastatine therapy in a group of 39 
SLOS patients. Positive effects of simvastatin on anthropometric measurements could 
not be confirmed, On the other hand, a negative effect of simvastatin on physical de-
velopment and behavioural problems could not be excluded (27). In summary, oral 
cholesterol supplementation may have a positive effect on photosensitivity, behaviour 
and growth in SLOS patients (II/B).
Desmosterolosis
Desmosterolosis is caused by deficiency of 3β-hydroxysterol ∆24-reductase, which 
catalyses the reduction of the ∆24 double bond of sterol intermediates (such as des-
mosterol) in the cholesterol synthetic pathway. Two patients have been reported so far. 
The first was a premature infant with multiple lethal malformations and generalized 
accumulation of desmosterol. Malformations consisted of macrocephaly, a hypoplas-
tic nasal bridge, cleft palate, total anomalous venous drainage, clitoromegaly, short 
limbs and generalized osteosclerosis (28). The second patient showed a less severe 
phenotype at the age of four years. His clinical presentation included microcephaly, 
agenesis of the corpus callosum, dysmorphic facies, submucous cleft palate, persist-
ent patent ductus arteriosus, limb abnormalities and developmental retardation (29). 
Desmosterol was elevated in plasma and in cultured lymphoblasts. Parents of both 
cases had mildly elevated levels of plasma desmosterol suggesting autosomal recessive 
inheritance. Homozygous mutations in the DHCR24 gene were demonstrated in both 
cases (30). No treatment is currently available.
X-linked dominant chondrodysplasia punctata (Conradi-hunermann syndrome 
or happle syndrome) and Congenital hemidysplasia with Ichthyosiform nevus 
and Limb Defects (ChILD)
Chondrodysplasia punctata is a term used for a heterogeneous group of genetic dis-
orders characterized by abnormal foci of calcification in the cartilaginous skeleton 
(epiphysial stippling). X-linked dominant chondrodysplasia punctata (CDPX2) is a 
rare disorder consisting of skeletal, cutanous and ocular malformations (reviewed in 
(31). CPDX2 almost exclusively affects females although a few affected males have 
been reported (31). Cutaneous manifestations contain ichtyosis, patchy alopecia and 
atrophoderma. Skeletal abnormalities include epiphysial stippling, asymmetric rhi-
zomelia and scoliosis. Ocular malformations are cataracts, microphtalmus, nystagmus, 
glaucoma and optic nerve atrophy. Intelligence is usually normal. Other abnormali-
ties (dysmorphic facies, and renal or cardiac manifestations) have been described. 
CDPX2 is caused by deficiency of 3β-hydroxysteroid-∆8-∆7-isomerase which cataly-
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ses a step in the conversion of lanosterol to cholesterol. The enzyme defect leads to 
accumulation of 8-dehydrocholesterol and 8(9)-cholestenol in plasma and tissues. 
Mutations in the gene encoding the emopamil-binding protein, which functions as a 
3β-hydroxysteroid-∆8-∆7-isomerase, have been identified as the underlying genetic 
defect and to date at least 46 different mutations have been described (32). The patho-
genesis of CDPX2 remains to be investigated. 
CHILD syndrome is an x-linked disorder with phenotypical similarities to CPDX2, but 
with a remarkable unilateral distribution of anomalies. Unilateral skin lesions, charac-
teristically a large epidermal plaque or nevus, are usually present at birth and persist 
throughout life. Unilateral hypoplasia of limbs and internal organs located at the 
same side as the skin lesion can be present. Cataracts are not reported in CHILD syn-
drome and the skeletal malformations are more severe compared to those in CPDX2, 
reviewed in (31, 33). Approximately 30 patients have been reported amongst which 
2 males. The defective gene underlying CHILD syndrome has been identified to be 
NSDHL, encoding the enzyme 3β-hydroxysteroid dehydrogenase (34). Treatment of 
CDPX2 and CHILD syndrome is symptomatic.
hydrops-ectopic Calcification-Moth-eaten Skeletal Dysplasia (heM or Green-
berg dysplasia) 
HEM is a rare, in utero lethal, skeletal dysplasia characterized by polyhydramnios, 
hydrops, dysmorphic facies and short-limbed dwarfism. About 10 cases have been 
described in the literature. 
HEM is caused by a deficiency of the enzyme 3β-hydrosterol ∆14-reductase caused by 
mutations of the LBR gene encoding the lamin B receptor (35).
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Table 2. recommendations for the treatment of inborn errors in cholesterol biosynthesis









Hids symptomatic treatment of fever and pain:      
 - nsaids




thalidomide and colchicine are not 
recommended







slos oral cholesterol supplementation 
(20-150 mg/kg/d) may have a positive effect on 
photosensitivity, behaviour and growth
ii/b
desmosterolosis no treatment available
conradi-Hunerman symptomatic treatment 
cHild symptomatic treatment 
Hem no treatment available
Inborn errors in bile acid and cholesterol biosynthesis
37
2
INBORN ERRORS IN BILE ACID 
SyNTHESIS
The conversion of cholesterol into the primary bile acids CA and CDCA is disturbed 
in a number of inborn bile acid synthesis defects (BASD). BASD are rare, with an 
estimated incidence of 1-2% of childhood cholestasic diseases (36). BASD can lead 
to cholestasis and impaired hepatic function based on accumulation of (toxic) inter-
mediates, unusual bile acids and bile alcohols. The lack of competent bile acids in the 
intestine will frequently cause malabsorption of dietary fat and fat-soluble vitamins., 
The recognition of BASD was accelerated after the implementation of an international 
screening program for genetic causes of cholestatic liver disease at the Cincinnati 
Children’s Hospital Medical Center in 2000 (37). Identification of BASD relies on fast 
atom bombardment ionisation-mass spectrometry (FAB-MS) or liquid secondary ion 
mass spectrometry (LSI-MS) of urine and serum to measure absence or reduction of 
the normal primary bile acids and accumulation of atypical bile acids or bile alcohols 
(37). Sequencing of genomic DNA has led to identification of responsible genes in 
most of the cases. Three clinical symptoms should lead to suspicion of a BASD in 
patients with cholestatic liver disease. First, most BASD are associated with normal 
to low serum bile acid concentrations, as determined by the conventional laboratory 
methodologies based on availability of substrates for 3 alpha steroid dehydrogenase, 
in contrast to elevated bile salt concentrations in other cholestatic liver diseases. Sec-
ond, serum γ glutamyl transpeptidase (GGT) is usually normal in BASD compared to 
most other other cholestatic liver diseases (except for Progressive Familial Intrahe-
patic Cholestasis type 1 or type 2). Third, pruritis, which is common in cholestatic 
liver disease, is usually absent in BASD (38). The clinical picture of BSAD depends 
on the specific defect. In general, defects in modification of the sterol nucleus fre-
quently present with neonatal progressive cholestatic liver disease whereas defects 
in modification of the side chain cause more neurological symptoms and less severe 
liver disease. Early recognition of BASD is essential because several of these conditions 
are treatable with oral bile acid supplementation. General features of inborn errors 
in bile acid synthesis are depicted in Table 3. Key points and recommendations in the 
treatment of inborn errors in bile acid synthesis are displayed in Table 4. Due to their 
low incidence, there is little evidence for therapeutic interventions for inborn errors 
in bile acid synthesis.  
DEFECTS INVOLVING MODIFICATION 
OF STEROL NUCLEUS
Cholesterol 7α-hydroxylase deficiency (CYP7a1)
The most recently described disorder of modification of the sterol nucleus is cholesterol 
7α- hydroxylase deficiency, in which bile acid synthesis via the ‘classical pathway’ is 
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Table 3. Features of inborn errors in bile acid synthesis. adapted from sundaram et al  (8)
Deficient enzyme Gene Clinical features BA profile (urine) BA profile (serum) Prevalence Animal  model
cholesterol 7α-hydroxylase 
(ec 1.14.13.17)
cYp7a1 adult patients: 
↑ serum ldl levels, resistant to statin therapy
Hypertriglyceridemia
cholesterol gall stones 
 









conjugates of  3β-δ5-
monohydroxy ba 
↑↑  ba level ( 3β-δ5-
monohydroxy ba)





3β-Hsd cholestasis in children at any age ↓ primary ba
↑ dihydroxy and trihydroxy-    
cholenoic acids




rapid progression to cirrhosis
GGt can be elevated
↓ primary ba
↑ 3-oxo-4 bile acids
↑ allo ba
↓ primary ba
↑ 3-oxo-4 bile acids
↑ allo ba
± 5-10 cases -
sterol 27-hydroxylase 
(ec 1.14.13.15)
cYp27a1 adults (20-30 years)
  - neurological dysfunction
  - dementia
  - cerebellar ataxia
  - cataracts
  - premature atherosclerosis
  - xanthomas
infancy
  -juvenile cataracts
  -chronic diarrhoea
  -neonatal cholestasis








amacr adult onset peripheral neuropathy
neonatal cholestasis
↓ primary ba








± 5 cases amacr -/- 
mouse (4)
Zellweger syndrome peX(1-12) malformations in various organ systems
Frequently lethal within 2 years of age 
↓ primary ba (a)
atypical mono-,di-, and 
trihydroxy c-27 ba (a)
↓ primary ba (a)
↑ long-chain fatty acids (a)
↑ cholestanoic acid (a)
↑  pipecolic acid (a)
↑ c29 dicarboxylic acid (a)
many cases several peX 
knock-out mice 
(5-7)
bile acid conjugation defects
(ec 2.3.1.65)
baat Fat-solube vitamin deficiency 
(transient) neonatal or childhood cholestasis
Unconjugated ca onconjugated ca and 
cdca
± 5 cases -
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Table 3. Features of inborn errors in bile acid synthesis. adapted from sundaram et al  (8)
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↓ primary ba (a)
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trihydroxy c-27 ba (a)
↓ primary ba (a)
↑ long-chain fatty acids (a)
↑ cholestanoic acid (a)
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↑ c29 dicarboxylic acid (a)
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baat Fat-solube vitamin deficiency 
(transient) neonatal or childhood cholestasis
Unconjugated ca onconjugated ca and 
cdca
± 5 cases -
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Tabel 4. Key points and recommendations for the treatment of inborn errors in bile acid biosynthesis
Recommendations and key points Level of 
evidence
General basd present most frequently as neonatal 
cholestasis
presentation as chronic liver disease in older 
patients occurs
in contrast to other cholestatic liver diseases, 
patients with basd commonly present with: 
- normal serum GGt 
- low serum bile acid levels
- pruritus is usually absent 
suspicion of, and early diagnosis of basd is 
important, as subsequent early treatment with 









oral cdca or ca and cdca combined




oral cdca combined with ca (8 mg/kg/d)
caution with the use of cdca in patients with 
normal/high serum concentrations of cdca
oral Udca insufficient as sole therapy
iii/b
ctX children: oral  cdca 15 mg/kg/d 
adults: oral cdca 250 mg/d
treatment should be started before the onset 
of neurological symptoms. 
i/b
amacr oral ca and fat-soluble vitamins iii/b
Zellweger syndrome treatment is supportive
bile acid conjugation 
defects
suggested therapy is oral primary ba and fat-
soluble vitamins
-
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decreased. A prominent feature in adult homozygous patients is an elevated serum 
LDL level, resistant to statin therapy, elevated serum triglycerides, and decreased (fecal) 
bile acid excretion Patients may present with cholesterol gallstones, but liver disease is 
not observed. Heterozygous subjects presented with milder dyslipidaemia (39). 
Oxysterol 7α-hydroxylase deficiency (CYP7B1)
Deficiency of the oxysterol 7α-hydroxylase, results in a defective conversion of 
27-hydroxy-cholesterol to 7α, 27-dihydroxy-cholesterol. Only two cases of oxys-
terol 7α-hydroxylase deficiency have been described so far (40, 41). The first child 
presented with cholestasis, elevated transaminases and normal GGT at the age of six 
weeks. Hepatic failure with clotting anomalies was present. The serum concentration 
of total bile acids was low and GC-MS analysis revealed the presence of 3-β-hydroxy-
5-choleonic and 3-β-hydroxy-5-cholestenoic acids. Serum analysis showed high 
levels of 27-hydroxy-cholesterol, while 7α-hydroxylated sterols were absent, sug-
gesting a defect at the level of oxysterol 7α-hydroxylase. Genetic analysis revealed 
a homozygous mutation of CYP7B1. Liver biopsy findings consisted of cholestasis, 
bridging fibrosis, giant cell transformation and proliferation of bile ductules. Treat-
ment with oral UDCA worsened liver function tests and the child was ineffectively 
treated with oral CA, after which he was subjected to orthotropic liver transplanta-
tion (OLT). The second case, a Taiwanese infant of non-consanguineous parents pre-
sented with progressive jaundice at the age of 5 months. Laboratory investigations 
showed elevated transaminases, a normal GGT and conjugated hyperbilirubinaemia. 
Mass spectrometry in urine revealed large amounts of sulfate or glycosulfate con-
jugates of monohydroxycholeonic acids, while “normal bile” acids were absent. In 
serum, over 90% of bile acids consisted of 3β-hydroxy-5-cholenoic and 3β-hydroxy-
5-cholestanoic acid. Liver biopsy findings were consistent with cirrhosis and bile duct 
proliferation accompanied by giant cell transformation. Genetic analysis showed a 
homozygous mutation in CYP7B1. Treatment with oral UDCA did not improve liver 
function or cholestasis. CDCA and CA could not be administered because of non-
availability in Taiwan. The patient was referred for OLT, but died of cholestatic liver 
failure before OLT could be performed. 
3β-hydroxy-∆5-C27-Steroid Dehydrogenase deficiency (3β-hSD deficiency)
The second step in the bile acid synthesis is catalyzed by 3β-hydroxy-C27-steroid dehy-
drogenase. Deficiency of this enzyme leads to accumulation of 7α-hydroxycholesterol 
in hepatocytes. As side chain oxidation and hydroxylation of 7α-hydroxycholesterol 
by other enzymes progresses, 3β, 7α-dihydroxy-5-choleonic acid and 3β, 7α, 12α 
-trihydroxy-5-choleonic acid will be formed. These non-functional bile acids un-
dergo sulphation, and are found in high concentrations in urine and plasma (42). 
Diagnosis of 3β-HSD-deficiency includes demonstration of abnormal bile acids in 
urine or plasma using mass spectrometry. 3β-HSD expression in fibroblasts is absent 
in affected subjects (43). Several disease-causing mutations have been identified (44). 
3β-HSD deficiency is a rare autosomal recessive disease with a broad clinical spec-
trum. Clinical manifestations in children may begin at any age and include cholestasis 
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with jaundice, fat-soluble vitamin deficiency and steatorrhea. Serum transaminases 
and serum bilirubin are elevated, but the serum GGT is usually normal (42;45). In 
1999, Akobeng reported two patients with 3β-HSD deficiency, who presented with 
rickets at the ages of seven and nine months, but did not develop clinical signs of 
liver disease until the age of three years (45). Cholestasis has been identified in adult 
patients as well, the oldest case being 26 years at the time of diagnosis (46). The late 
onset cholestasis is usually preceded by a transient elevation of serum transaminases 
in the neonatal period. Histopathological findings in the liver, ranging from giant cell 
hepatitis to cirrhosis, depend on the age of the patient and on the rate of progression 
of liver disease. The therapeutic approach includes oral administration of primary bile 
acids. The rationale behind primary bile acid therapy is that these primary bile acids 
provide bile acid-dependent bile flow, counteracting cholestasis, as CYP7A1 is sup-
pressed by cholic acid (CA) and chenodeoxycholic acid (CDCA), thereby reducing 
the production of the abnormal bile acids. Treatment with oral CDCA (doses ranging 
from 9-18 mg/kg/d) resulted in marked clinical, biochemical and histological im-
provement (45, 47). Kobayashi showed that combined therapy with CDCA and CA 
was more effective than CDCA alone in the treatment of a 23 year old woman with 
3β HSD deficiency (48). Treatment with oral ursodeochycholic acid (UDCA) may be 
of temporary benefit (49) but its long term effect will be limited, because UDCA is 
not capable of suppressing bile acid synthesis (42).
Thus, oral supplementation of CDCA results in improvement of clinical, biochemical 
and histological features (III/B). Oral supplementation of CDCA combined with CA 
was more effective than CDCA treatment alone, in an adult patient (III/B).
3-oxo-∆4-steroid 5β-reductase deficiency (5βrD)
3-oxo-∆4-steroid 5β-reductase deficiency is an autosomal recessive disease caused 
by mutations in the gene AKR1D1 (previously known as SRD5B1). 5 βRD was first 
described by Setchell et al. in identical twins suffering from neonatal hepatitis and 
progressive cholestasis (50). Deficiency of 5βRD impairs the reduction of the double 
bond between C4 and C5 of the sterol nucleus, and the conversion of 3-oxo interme-
diates to their corresponding 3α-hydroxylated products. Urine and plasma levels of 
primary bile acids are low and intermediate bile acid synthesis products proximal to 
the enzyme defect (3-oxo-4 bile acids) accumulate, and are detectable by mass spec-
trometry (36). However, hyper-3-oxo-∆4 bile aciduria is also seen in children with 
cholestatic liver disease other than inborn errors in bile acid synthesis (e.g. tyrosine-
mia, α-1-antitrypsin deficiency), rendering it difficult to distinguish between prima-
ry 5 βRD-deficiency and secondary inhibition of the enzyme by liver damage (51). 
As 3-oxo-∆4-steroid 5β-reductase is not expressed in fibroblasts or leukocytes, cell 
based enzyme activity studies are not available. Definite diagnosis of 3-oxo-∆4-steroid 
5β-reductase deficiency depends on demonstrating mutations in AKR1D1 (52, 53). 
Approximately 10 patients with 5βRD have been described (41, 54). The clinical pic-
ture resembles that of 3β-hydroxy-∆5-C
27
-steroid dehydrogenase deficiency; neonatal 
cholestasis with elevated plasma concentrations of aminotransferases and conjugated 
bilirubin. Yet GGT can be elevated in 5βRD. Malabsorption of the fat-soluble vitamin 
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D may cause rickets. Infants with 5βRD tend to have more severe liver disease at an 
earlier age compared to 3βHSDH. Hepatic histopathology is typical of neonatal hepa-
titis, with giant cell hepatitis, pseudoacinar transformation, hepatocellular and canal-
icular cholestasis and extramedullary haematopoiesis (36). Liver failure will progress 
rapidly, and without treatment the mortality rate is about 50% (36). 
Oral administration of CDCA and CA (both at a dose of 8 mg/kg/d) improved liver 
disease, both clinically and biochemically (53, 55). Caution with the use of CDCA in 
patients with normal/high serum concentrations of CDCA should be urged, because 
CDCA is potentially hepatotoxic (55). The choleretic bile acid UDCA is frequently 
used in pediatric cholestatic diseases. In 5βRD, UDCA is insufficient as sole therapy, 
probably because UDCA does not exert a strong negative feedback on bile acid syn-
thesis via CYP7A1 (55). Concluding, oral supplementation of CDCA combined with 
CA improved clinical, biochemical and histological features (III/B).
DEFECTS IN SIDE CHAIN MODIFICATION 
Cerebrotendinous xanthomatosis (CtX)
CTX is a rare autosomal recessive lipid storage disease caused by the deficiency of the 
mitochondrial enzyme sterol 27-hydroxylase, which results in impaired side chain 
modification during bile acid synthesis. The intermediates 5β-cholestane-3α,7α,12α-
triol and 5β-cholestane-3α,7α-diol are not hydroxylated at the c-27 position and 
therefore side-chain oxidation to the usual C24-primary bile acids cannot take place. 
These intermediates are hydroxylated at multiple sites to form bile alcohols which 
become glucuronidated. The production of primary bile acids, in particular CDCA, 
is reduced while bile alcohol glucuronides (which are diagnostic) accumulate. Some 
CA can still be synthesized via an alternative C-25 hydroxylation pathway. The absent 
negative feedback of primary bile acids on CYP7A1 leads to the accumulation of 
cholestanol which results in its deposition in various tissues. The molecular defect of 
CTX was identified to reside in the sterol 27-hydroxylase gene (CYP27A1) (56) and 
over 50 different mutations have been described (57).
Plasma concentrations of cholestanol are increased, whereas cholesterol concentra-
tions are normal. Large amounts of bile alcohol glucuronides are excreted in bile, 
faeces and urine. Patients usually present in the second or third decade of life with 
various symptoms, including progressive neurological dysfunction, dementia, cer-
ebellar ataxia, cataracts, premature atherosclerosis and the presence of xanthomas in 
tendons and brain (57). Chronic diarrhoea and juvenile cataracts may precede the 
onset of neurological symptoms, and a few paediatric cases have also been reported 
(58). Although liver disease is not observed in CTX, neonatal cholestasis due to muta-
tions in the CYP27A gene has been described (59). Diagnosis is based on an increased 
plasma cholestanol/cholesterol ratio and the detection of increased levels of bile al-
cohol glucuronides in urine. Definitive conformation of the diagnosis is achieved 
by analysis of the CYP27A1 gene. For the treatment of CTX, several approaches have 
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been tried of which oral administration of CDCA was most effective (60). Berginer et 
al. showed clinical and biochemical improvement in 17 adult CTX patients, upon ad-
ministration of CDCA (750 mg/d) for at least one year (61). Comparable results were 
found after treatment of paediatric CTX patients with CDCA (15 mg/kg). (58)  Clini-
cal improvement was most notable if CDCA treatment was initiated before the onset 
of significant (neurological) symptoms (62). UDCA is not effective in treatment of 
CTX (60, 63). Statins have been studied as a treatment regime for CTX. Even though 
data are limited, there is no evidence supporting  statin monotherapy as treatment for 
CTX (63). Statins combined with CDCA treatment showed additional reduction of 
cholestanon in one patient (64). The addition of simvastatin (10-40 mg/d) to CDCA 
did lower serum levels of cholestanol in seven patients, however, additional clinical 
improvement was not objectified (65).  In summary, oral supplementation of CDCA 
(15 mg/kg/d in children and 250 mg/d in adults) improved clinical and biochemi-
cal features in CTX patients (I/B). Treatment should be initiated before the onset of 
neurological symptoms.
alpha-Methylacyl-Coa racemase (aMaCr) Deficiency
AMACR deficiency is an autosomal recessive defect impairing the side-chain 
oxidation. AMACR catalyzes the racemation of trihydroxycholestanoic acid 
and pristanic acid into their stereo-isomers. This conversion is required for 
the subsequent peroxisomal β-oxidation of the C27 bile acid side-chain. AMACR 
deficiency affects both bile acid and fatty acid synthesis, resulting in elevated levels 
of pristanic acid and trihydroxycholestanoic acid in urine and plasma. Ferdinandusse 
described two patients presenting with adult-onset periferal neuropathy and one with 
symptoms resembling Niemann-Pick type C in childhood (66). A two week old infant 
with fat-soluble vitamin deficiency, cholestasis and hematochezia was described. This 
infant had a sibling who became a liver transplant donor after death in infancy because 
of intracranial hemorrhage due to vitamin K deficiency. The transplant recipient was 
diagnosed with AMACR deficiency. Diagnosis was confirmed with absence of AMACR 
activity, an abnormal bile acid profile, increased plasma pristanic acid concentrations 
or mutations in the AMACR gene. The two week old infant and her siblings liver 
recipient were successfully treated with oral CA and fat-soluble vitamins (67). For 
the treatment of AMACR deficiency oral supplementation of CA combined with fat-
soluble vitamins may improve clinical, biochemical and histological features (III/B).
Zellweger syndrome (ZS or cerebro-hepato-renal syndrome) 
The final steps of bile acid synthesis take place in peroxisomes: beta-oxidation of the 
side-chain of specific bile acid intermediates. ZS is an autosomal recessive disorder in 
which peroxisomes are absent. Patients have dysmorphic facies, hypotonia, chronic 
liver disease, psychomotor retardation and renal cystic abnormalities. ZS is frequently 
lethal within two years of age. Mutations in 12 genes, PEX1 to PEX12, have been 
identified with PEX1 being the most common affected gene in ZS (reviewed in (68). 
Amongst biochemical abnormalities, hyperpipecolic acidemia and increased plasma 
levels of monohydroxy, di-and trihydroxy bile acids with elongated side chains 
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are found whereas levels of primary bile acids are reduced (68). Other, less severe 
peroxisomal disorders (Refsum disease and neonatal adrenoleukodystrophy) 
have been associated with abnormal bile acid synthesis. The treatment of these 
conditions is supportive. 
BILE ACID CONJUGATION DEFECTS
The two enzymes catalysing the final step in bile salt synthesis (conjugation of CA 
and CDCA to taurine or glycine) are bile acid-CoA ligase enzyme and CoA:amino acid 
N-acyltransferase (encoded by the genes BAAT and BALT) (69, 70). Unconjugated 
bile acids are more rapidly absorbed in the intestine. Due to the decreased secretion 
of conjugated bile acids, less mixed micelles can be formed. The main feature in 
patients with bile acid conjugation defects is severe malabsorption of fat and fat 
-soluble vitamins in infancy or childhood. Conjugated hyperbilirubinemia, pruritis 
and liver failure have also been described. Mass spectrometry analysis on urine, bile 
and serum reveals absence of glycine- and taurine conjugated bile acids whereas 
unconjugated CA and glucuronide- and sulphate conjugates are present. (reviewed in 
Ref. 38). Mutations in the gene BAAT have been found in several Amish patients with 
this clinical picture (69). Supplementation with oral primary conjugated bile acids 
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Intrauterine malnutrition is associated with increased susceptibility to chronic diseas-
es in adulthood. Growth-restricted infants display a less favorable lipid profile already 
shortly postnatal. Maternal low protein diet (LPD) during gestation is a well-defined 
model of fetal programming in rodents and affects lipid metabolism of the offspring. 
Effects of LPD throughout gestation on physiological relevant parameters of lipid me-
tabolism are unclear. We aimed to determine effects of gestational LPD on maternal-
fetal cholesterol fluxes and fetal lipid synthesis in mice. 
Methods
Pregnant mice (dams) were fed a control (18% casein) or a low protein diet (9% ca-
sein) from E0.5 onward. We quantified maternal-fetal cholesterol transport and ma-
ternal cholesterol absorption at E19.5 using stable isotopes. We determined fetal lipid 
biosynthesis at E19.5, after administration of [1-13C]-acetate from E17.5 onward. 
results 
LPD did not change fetal and maternal plasma and hepatic concentrations of choles-
terol and triglycerides. LPD affected neither the magnitudes of maternal-fetal cho-
lesterol flux, maternal cholesterol absorption, nor fetal synthesis of cholesterol and 
palmitate (both groups, ~14% and ~13%, respectively). 
Conclusion 
We conclude that LPD throughout gestation in mice does not affect maternal-fetal 
cholesterol transport, fetal cholesterol or fatty acid synthesis, indicating that program-
ming effects of LPD are not mediated by short-term changes in maternal-fetal lipid 
metabolism.




Epidemiological studies indicate that inadequate intrauterine nutrition is associated 
with increased susceptibility to develop chronic diseases in adulthood (e.g. diabetes, 
hypertension and cardiovascular disease; ‘metabolic programming’) (1). Compara-
bly, associations between small body size at birth and a less favourable lipid profile 
in adulthood have been described (2-4). Already in the first postnatal days, growth 
restricted human infants display a more atherogenic lipid profile (increased plasma 
concentrations of triglycerides, total cholesterol and LDL-cholesterol) compared with 
infants with a birth weight appropriate for gestational age (5). 
Elevated plasma cholesterol is an established risk factor for the development of car-
diovascular diseases later in life, however, insufficient cholesterol supply to the fetus 
impairs its development (6). It was demonstrated that the fetus is capable of synthesiz-
ing a large fraction of the required cholesterol de novo (7-9). As an independent source 
of cholesterol, maternal cholesterol can be transported to the fetal circulation (10). Re-
cently it was shown that maternal-fetal cholesterol transport is influenced by maternal 
plasma cholesterol levels (11). Interestingly, high maternal cholesterol levels increase 
the development of fetal aortic fatty streaks, as shown in human and animal studies 
(12, 13). Hence, the metabolic condition of the mother during pregnancy can affect 
lipid metabolism in the offspring. 
In humans, exposure to the Dutch Hunger Winter during late gestation is associ-
ated with increased adult obesity, glucose intolerance, and hypertension (14). Several 
animal models were developed to mimic the caloric restriction during gestation. An 
established animal model to investigate metabolic consequences of gestational under 
nutrition in the offspring, is a low protein diet during gestation  (15).
Studies in rats have indicated that maternal protein restriction during gestation leads to 
features of the metabolic syndrome in adulthood, e.g., increased blood pressure (16), 
decreased insulin sensitivity and alterations in lipid profile (17, 18). In mice, ma-
ternal protein restriction during pregnancy impaired glucose clearance in the adult 
offspring (19). Furthermore, experiments in mice showed that an LPD 
affected the renin-angiotensin system (important in the regulation of blood pressure) 
in the fetus already (20). 
Recently, we demonstrated in mice that maternal gestational protein restriction re-
duced the expression of genes involved in lipid synthesis and cholesterol metabolism 
in the fetal liver (21). Because the liver is a key player in regulating cholesterol and 
fatty acid homeostasis, we hypothesized that changes in fetal hepatic gene expression 
could translate into short term (“acute”)  effects on cholesterol and fatty acid metab-
olism (such as maternal-fetal cholesterol flux and/or fetal cholesterol and lipid syn-
thesis). If true, short-term effects on fetal lipid metabolism could be involved in the 
mechanism by which metabolic programming takes place. We aimed to determine 
the acute effects of maternal protein restriction during gestation on maternal-fetal 






C57BL/6J mice (age 20 ± 1 wk) were obtained from Harlan (Horst, The Netherlands). 
Animals were housed in temperature-controlled rooms (23 °C) with 12-h light cycling, 
and free access to standard RMH-B mouse chow before the experiments (Arie Blok 
BV, Woerden, The Netherlands) and water ad libitum. Experimental procedures were 
approved by the local Ethical Committee for Animal Experiments of the University 
of Groningen.
experimental procedures
All female mice received the control diet containing 180 g casein/kg (purified diet, 
4400.18, Arie Blok BV, Woerden, The Netherlands) 2 weeks before mating. Virgin 
females were time mated using vaginal smears to assess their stage of estrous before 
introducing the male. After confirmation of mating by detection of a vaginal plug, 
the females were allocated to either the control diet or the isocaloric low protein 
diet (90g casein/kg, purified diet 4400.17, Arie Blok BV, Woerden, The Netherlands) 
during the gestational period. The experimental diets are identical to the diets used by 
Langley-Evans et al. (22) and are described in detail in Table 1. We originally planned 
an independent intervention study with a fourth experimental group (n=5) and 
own controls (n=5). However, the intervention was not executed, in contrast to the 
control treatment in the second group of five (control) mice. Because the design on 
the control group was identical, we considered it scientifically appropriate to include 
the control mice into this study, although it caused unequal distribution (n = 10 for 
controls and n = 5 for treated dams).
Animals were weighed every two d. On embryonic day 14.5 (E14.5) pregnant mice 
received an i.v. dose of 0.52 mg (1.265 μmol) cholesterol-D
7
 dissolved in Intralipid® 
Table 1. composition of the diets provided
Component (g per 100g diet) Control Diet (18% casein) Low Protein Diet (9% casein)
casein 18.00 9.00
sucrose 21.30 24.30
corn starch 42.5 48.50
cellulose Fibre 5.00 5.00
vitamin mix ain-76 0.12 0.12
mineral mix ain-76 0.12 0.12
corn oil 10.00 10.00
choline choride 0.20 0.20
methionine 0.50 0.50
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(20%, Fresenius Kabi, Den Bosch, The Netherlands) and an oral dose of 0.97 mg 
(2.30 μmol) cholesterol-D
5
 dissolved in medium-chain triglyceride oil. Weights of 
the dams ranged from 27.3 to 33.1 g at E14.5 of gestation and were not signifi-
cantly different between the two dietary groups. From E17.5 onward both diets were 
supplemented with 10 mg/g [1-13C]-acetate (Isotec, Miamisburg, OH, USA). Blood 
spots were collected from the tail on filter paper before administration of labeled cho-
lesterol and acetate and daily from E14.5 onward until E19.5 of gestation. At E19.5 
females were anaesthetized with isoflurane and terminated by cardiac puncture. Fig-
ure 1 shows a schematic overview of the experimental set-up
Blood was collected in EDTA tubes. Liver and brain were snap frozen in liquid nitrogen. 
Fetuses were removed from uteri, weight and length were measured, and fetuses were 
killed and dissected. Blood samples were taken by exsanguination. Liver and brain of 
fetuses were collected, immediately snap frozen in liquid nitrogen and stored at -80 °C. 
Sex of the fetuses was determined by PCR as previously described (23, 24)
 
analytical procedures
Cholesterol was extracted from blood spots and plasma according to Neese et al (25). 
Hepatic and brain lipids from mothers and pups and lipids from whole (complete) 
pups were extracted according to Bligh and Dyer (26). Unesterified cholesterol from 
blood spots, plasma and tissues were analyzed by gas chromatography quadrupole 
mass spectrometry (27). Commercially available kits were used for the determination 
of total cholesterol in brain, liver and plasma samples (Roche, Mannheim, Germany). 
Hepatic fatty acids from livers of mothers and fetuses were analyzed by gas chroma-
tography quadrupole mass spectrometry according to Oosterveer et al (28). In short, 
lipids were extracted from livers, and were hydrolyzed using HCl and acetonitril. 
Fatty acids were extracted with hexane, after which the samples were derivatized us-
ing pentafluorobenzyl:triethanolamine:acetonitril solution. Enrichments of the PFB-
derivatives of palmitate were measured by gas chromatograpy-mass spectrometry. The 
ion monitored were m/z 255-259 corresponding to the m0-m4 mass isotopomers 
for C16:0. 
E 14.5 19.517.50






Figure 1. experimental set-up.
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Fractional cholesterol absorption measurement
Fractional cholesterol absorption was measured using an adapted plasma dual isotope 
ratio method (29) using blood spots obtained at 120 h after i.v. and oral administration 
of stable-isotopically-labeled cholesterol. For calculation of the fractional cholesterol 




-cholesterol in blood spots was divided 




-cholesterol in the administered dose. The resulting 
value represents the fractional cholesterol absorption (27). 
Mass isotopomer distribution analysis (MIDa) 
To determine de novo cholesterol and palmitate synthesis, the MIDA approach was used 
(25, 30). MIDA allows determination of the enrichment of the pool of acetyl-CoA 
precursor units that has entered newly synthesized cholesterol or palmitate molecules 
during the course of [1-13C]-acetate administration. Analysis of the isotopomer pattern 
of these molecules allows for determination of the fraction (f) of newly synthesized 
cholesterol or palmitate, respectively in plasma or tissue. All normalized mass isoto-




) were corrected for the natural 
abundance of 13C by multiple linear regression as described by Lee (31) et al. to obtain 




) due to incorporation 
of the infused [1-13C]-acetate as described in Ref 28. For determination of the absolute 
amount of newly synthesized hepatic palmitate, we multiplied f by the total amount of 
hepatic palmitate at the end of the experiment. 
Statistics
We regarded the whole litter as one experimental unit, according to Festing (32). 
All data are presented as means ± SD. Statistical analyses were performed using SPSS 
14.0 for Windows software (SPSS Inc., Chicago). All data were analyzed using the 
Mann-Whitney-U-test with a p <0.05 considered significant.
RESULTS
Parameters in the control group
As stated above, the group size of the control mice was twice that of the experimental 
(low protein) intervention, based on the original design of two control groups of 
each n=5, undergoing identical (control) treatment. We analyzed whether results 
between the two n=5 control mice differed, but the parameters measured were 
virtually identical. Based on this observation, we pooled the data of the n=10 control 
mice. 
LPD affects body weight in dams but not in fetuses
At E0.5, there was no difference in body weight of dams between both groups. At 
E19.5, dams on a LPD had lower body weights than control dams (Table 2. Food 
intake during gestation was not different until E17.5 (data not shown), but was lower 
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in dams on a LPD between E17.5 and E19.5. There was no significant difference in 
the other parameters analyzed, including liver weight to body weight ratio of dams, 
litter size, body weight, body length or liver weight to body weight ratio in fetuses 
(Table 2).
LPD does not affect total cholesterol concentrations in tissues
To investigate whether protein restriction diet during gestation influenced total cho-
lesterol concentrations in dams and fetuses, we measured total cholesterol in tissues 
on E19.5. Figure 2A shows that total cholesterol levels in liver or brain in dams did 
not significantly differ between the two groups. In fetuses, protein restriction did not 
significantly affect total cholesterol levels in liver, brain, or whole body (the complete 
fetus; Fig. 2B).
LPD does not affect maternal fractional absorption of cholesterol
We investigated whether the LPD quantitatively affected cholesterol absorption in the 
dam and cholesterol transport to the fetus during the last stage of gestation. Choles-
terol absorption in dams was found to be 64 ± 8% in control dams and 67 ± 8% in 
low protein (NS).
LPD does not quantitatively affect maternal-fetal cholesterol transport
Maternal-fetal transport of cholesterol was determined by measurement of the fraction 
of labeled cholesterol in several tissues of dams and fetuses at E19.5. To determine 
Table 2. parameters of dams and fetuses at e19.5 of gestation
 Parameter Control diet Low protein diet
weight dam (g) 35.6 ± 2.0 32.1 ± 1.0*
food intake dam (g/day) 6.3 ± 1.2 4.2 ± 0.7*
liver weight  
to body weight dam (%) 4.5 ± 0.4 5.0 ± 0.2
litter size (n) 7.3 ± 1.7 6.2 ± 2.1
weight fetus (g) 1.07 ± 0.11 0.99 ± 0.15
length fetus (mm) 20.4 ± 1.4 20.5 ± 1.5
liver weight  
to body weight fetus  (%) 2.8 ± 0.8 2.9 ± 1.1
parameters of c57bl/6J dams and fetuses at e19.5 of gestation receiving control diet or low protein 
diet during gestation. data are mean ± sd. n= 5 (low protein) and 10 (control) dams per group; *, p<0.05 
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whether the administration route to the dam influenced on cholesterol transport to 




-labeled cholesterol in tissue and plasma were 




 cholesterol was measured every 24 h 
after administration (E14.5) until termination (E19.5) and did not significantly differ 
between dams on LPD or on control diet (data not shown). 
The fraction of orally administered D
5
 cholesterol constituted about 0.5% of total 
cholesterol in livers and plasma of both groups. The fraction of orally administered 
D
5
 cholesterol in brain was near detection level in dams of both groups (Fig. 3A). In 
fetuses at E19.5, the fraction of D
5
 cholesterol was measurable in liver, plasma, brain 
and whole body, albeit very low in both groups (Figure 3B).
The fraction of i.v.-administered D
7
 cholesterol in plasma was higher in low protein 
dams compared with control dams (0.16 ± 0.04% in control dams and 0.36 ± 0.06% 
in low protein dams (p=0.028). In livers, this fraction was 2.2 ± 0.2% in control 












































Figure 2. total cholesterol levels in tissues of (A) dams and (B) fetuses. Whole body cholesterol in 
fetuses represents the amount of total cholesterol in the complete fetal body. open bars, control 
mice; closed bars, mice receiving an lpd during gestation. values represent the mean ± sd. n = 5 for 
low-protein dams and 10 for control dams.
























































Figure 3. Fractional enrichments of orally administrated d5–cholesterol in tissues of (A) dams and 
(B) fetuses and of i.v.-administrated d7-cholesterol in tissues of (C) dams and (D) fetuses at day 19.5 
of gestation. open bars, control mice; closed bars, mice receiving an lpd during gestation. values 
represent the mean ± sd. n = 5 for low-protein dams and 10 for control dams.
administrated D
7 
was below detection at E19.5 of gestation for both groups (Fig. 3C). 
In fetuses at E19.5, the fraction of D
7
 cholesterol was 1.0 ± 0.1% in liver of control 
fetuses and 1.1  ±  0.1% in liver of low protein fetuses. Fractions of D
7
 cholesterol in 
plasma brain and whole body of fetuses were detectable, but below 0.5% in both 





 cholesterol between control or low protein dams or fetuses.
LPD does not quantitatively affect maternal or fetal lipid synthesis
All dams received [1-13C]-acetate in the diet from E17.5 onward to investigate if re-
ceiving an LPD during gestation would influence cholesterol or palmitate synthesis in 
dams and fetuses in the last stage of gestation. Precursor pool enrichments were ~9% 
for control dams and low protein dams at 24 and 48h (Fig. 4A), indicating steady-
state and comparable levels of precursor pool enrichment in both groups. Fractional 
contribution of newly synthesized cholesterol was 11.9 ± 0.4% for control dams and 
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9.2 ± 2.7% for low protein dams at 24h (NS) and 17.0 ± 0.6% for control dams and 
14.9 ± 3.2% for low protein dams at 48h (NS, Fig. 4B). 
We determined the incorporation of newly synthesized cholesterol in the fetus by cal-
culating fractional newly synthesized cholesterol at E19.5 in different tissues of dams 
and fetuses receiving the control diet or the LPD using MIDA. Fractional synthesis in 
dams was 17.4 ± 0.6% in liver for control dams and 15.0 ± 3.0% in livers of low 
protein dams, 16.7 ± 1.5% in plasma of control dams and 14.4 ± 6.9% in plasma of 
low protein dams, 1.4 ± 0.4% in brain of control dams and 1.5 ± 0.4% in brain of low 
protein dams (all NS, Fig. 5A). 
Fractional synthesis in fetuses was 12.6 ± 0.5% in liver of control fetuses and 14.8 ± 
2.1% in liver of low protein fetuses, 13.1 ± 2.1% in plasma of controls and 15.4 ± 
5.3% in plasma of low protein fetuses, 3.3 ± 0.02% in brain of control fetuses and 4.0 
± 0.4% in brain of low protein fetuses, 9.7 ± 1.4% in whole body of control fetuses 





































Figure 4. Fractional precursor pool enrichment (A) and fractional contribution of newly synthesized 
cholesterol (B) in dams on a control diet (open circles) or an lpd (closed squares) during gestation. 
Fractions were measured making use of blood spots collected on filter paper (n = 5 for low-protein 
dams and 10 for control dams). dams received 13c-labeled acetate in the diet from day 17.5 of gestation 
onward. blood spots obtained 24 and 48 hours after administration were used for the calculations of 
the precursor pool enrichment and fractional contribution of newly synthesized cholesterol. values 
represent the mean ± sd.
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No significant differences were found in fractional cholesterol synthesis between 
dams and fetuses on a control diet compared with dams and fetuses on an LPD. 
Fractional and absolute de novo synthesis of palmitate (C16:0) in livers of dams and 
fetuses was calculated using MIDA. Fractional de novo synthesized palmitate was 23 ± 
2% in control dams and 23 ± 5% in low protein dams. Fractional de novo synthesized 
palmitate was 12.3 ± 0.4% in control fetuses and 14.8 ± 1.0% in low protein fetuses 
(Fig. 6A). Absolute de novo synthesis of palmitate was 7.3 ± 1.4 μmol/gram liver in 
control dams and 4.7 ± 0.9 μmol/gram liver in low protein dams (p 0.2). Absolute 
de novo synthesis of palmitate was 18.7 ± 1.4 μmol/gram liver in control fetuses and 
25.0 ± 2.8 μmol/gram liver in low protein fetuses (Fig. 6B). No significant differ-
ences considering fractional or absolute de novo synthesis of palmitate between the two 










































Figure 5. de novo fractional cholesterol synthesis in tissues of (A) dams and (B) fetuses. open bars, 
control mice; closed bars, mice receiving an lpd during gestation. 13c-acetate was administrated in 
the diet and fractional synthesis was calculated using mida. n = 5 for low-protein dams and 10 for 
















































Figure 6. de novo (A) fractional and (B) absolute palmitate (c16:0) synthesis in livers of dams and 
fetuses. open bars, control mice; closed bars, mice receiving an lpd during gestation. 13c-acetate 
was administrated in the diet and fractional and absolute synthesis were calculated using mida. n = 5 
for low-protein dams and 10 for control dams. values represent the mean ± sd.




A maternal LPD during the gestational period is a widely used animal model for intra-
uterine malnutrition to study the mechanisms underlying ‘metabolic programming’. 
The purpose of using this diet during gestation is to mimic intrauterine malnutrition 
and its possible metabolic consequences. Most frequently, the LPD has been applied 
in rats in which gestational protein restriction resulted in impaired nephrogenesis 
and hypertension (33), disturbed glucose tolerance, obesity and alterations in lipid 
metabolism (17) in the adult offspring. Several studies in mice demonstrate that ma-
ternal low protein during gestation leads to features of the metabolic syndrome in 
offspring. Male offspring from protein-restricted dams developed increased adiposity 
and glucose intolerance at adult age (34). When fed a high-fat diet, male offspring 
from protein-restricted dams show a higher increase in body weight, relative fat mass, 
hyperglycemia, hypercholesterolemia and hyperleptinemia, compared to high-fed 
diet offspring from control dams (35). Studying the metabolic effects of protein 
restriction during gestation in mice allows for extrapolation to studies on program-
ming effects in different knock out mice. In the ApoE*3-Leiden mouse, a model for 
development of atherosclerosis, maternal protein restriction “aggravated” the dyslipi-
daemia and induced more severe atherosclerotic lesions in female adult offspring fed 
an atherogenic diet (36). 
Some human and animal studies showed that metabolic programming has differential 
effects in adult male and female offspring, albeit inconsistent. In the present study, no 
differences between male and female pups in the studied parameters were observed. 
We used a unique stable isotope method to determine maternal-fetal cholesterol flux-




-labeled cholesterol to 
the dam enabled us to distinguish between cholesterol of different maternal sources 
transported from dam to fetus. The simultaneous administration of 13C-acetate to the 
dam allows determination of cholesterol and fatty acid synthesis in maternal and fetal 
organs.
In this study, the LPD slightly decreased maternal food intake and maternal weight, 
when compared to control diet. However, no differences in fetal weight or length were 
seen in protein-restricted fetuses compared with controls. The observation on fetal 
weight corresponds with several other studies using the same diet in rats (37, 38).
In previous experiments in mice, we showed that protein restriction during gestation 
decreased mRNA expression of genes important in cholesterol transport and fatty acid 
synthesis in fetal livers (21). These data supported the hypothesis that acute effects 
on lipid homeostasis could be related to the induction of programming. The present 
study, however, unequivocally demonstrates that maternal protein restriction during 
gestation does not induce acute, major quantitative changes in maternal-fetal choles-
terol transport, cholesterol biosynthesis or fatty acid biosynthesis in the last stage of 
pregnancy in mice.  Discrepancy between mRNA data and metabolic fluxes has been 
reported before, underscoring the notion that the ‘proof of the pudding’ of reporting 
changes in mRNA and even protein activities is in measuring the relevant metabolic 
fluxes in vivo.   
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Chapter 3
The fraction of i.v. administered cholesterol was significantly higher in plasma of the 
low protein dams compared with controls. This effect, however, was not reflected in 
the total plasma cholesterol levels of dams, or in the fractions of D
7
-labeled cholesterol 
in plasma or other tissues of pups. We therefore assume that the effect on i.v. fractions 
is of limited physiological relevance.
We do realize that a theoretical limitation of the present study is the rapidly changing 
metabolism of dam and fetus during gestation, which constitutes metabolically a 
“non-steady state” condition per definition. However, we feel that this limitation 
most likely applies equally for both the control and the low protein group, and does 
not invalidate our main conclusions. Another realization involves the timing of our 
experiment to the late stage of gestation. Theoretically, the protein restriction diet 
could have influenced cholesterol flux to the fetus in the first stage of gestation. We 
do not have indications for this possibility as we did not find any differences in total 
cholesterol content in fetal organs in the last stage of gestation. Based on the results, 
it seems reasonable to assume that the effects of the maternal diet on cholesterol 
fluxes and/or on fetal hepatic lipid synthesis during the first stage of gestation are 
negligible. The presently used model does allow determination of effects of the 
maternal environment on maternal-fetal transport and on fetal cholesterol and fatty 
acid synthesis. The method could be applicable to studies investigating the influence 
of various maternal conditions such as maternal overnutrition or maternal diabetes 
on fetal lipid metabolism. In conclusion, programming effects of maternal protein 
restriction during gestation are not accompanied by immediate changes in fetal-
maternal cholesterol transport or lipid synthesis in mice in the last stage of pregnancy. 
Apparently, programming effects of maternal LPD on lipid metabolism are more 
mediated by more complex pathways than these acute effects. 
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IUGR is linked to increased development of features of the metabolic syndrome in 
adulthood. IUGR results in small-for-gestational-age (SGA) neonates and is associated 
with elevated plasma cholesterol and triglyceride concentrations in neonatal and 
adult life. It is unclear whether these associations are based on increased cholesterol 
and fatty acid synthesis. 
aim 
We compared the rates of cholesterogenesis and de novo lipogenesis (DNL) in six SGA 
and eight appropriate-for-gestational-age (AGA) preterm infants. 
Methods and results 
[1-13C]-Acetate was administered intravenously for 24 hours in the first two postnatal 
days. We quantified DNL and cholesterogenesis in blood by mass isotopomer 
distribution analysis. During the study period, patients did not yet receive intravenous 
lipid emulsion and enteral intake was limited. Plasma cholesterol and triglycerides 
were comparable in SGA and AGA infants (cholesterol ~2 mM; triglycerides ~0.5 
mM). The fraction newly synthesized cholesterol in plasma free cholesterol (~13%) 
and the absolute cholesterol synthesis rate (~23 mg/kg/day) were similar in both 
groups. DNL was ~50% higher in SGA than in AGA infants: 9.3% vs. 6.1%, respectively; 
p<0.05. 
Conclusion 
We conclude that IUGR does not affect cholesterogenesis and slightly increases DNL. 
Our results also indicate that DNL does not strongly affect neonatal plasma triglyceride 
concentrations.




Epidemiological studies have linked IUGR to chronic diseases such as hypertension, 
coronary heart disease and type II diabetes in adulthood (8, 31). Additionally, 
IUGR is related to a more atherogenic lipid profile in later life (2, 12, 13, 16, 24, 
29). Interestingly, IUGR influences lipid profiles already in fetuses (14, 19) and in 
newborn infants. It has been shown that SGA neonates had higher plasma triglycerides 
(TG), total cholesterol (TC) and LDL (C) concentrations compared to AGA neonates 
within 72 hours after birth (30). Moreover, aortic wall thickening, an early marker 
of atherosclerosis in children, is increased in SGA compared to AGA neonates (16, 
27). The underlying mechanism linking IUGR to these short-term changes in lipid 
metabolism has remained unclear. 
In contrast, indispensible functions of cholesterol have been unraveled to a large extent. 
Cholesterol serves as a structural membrane component and a precursor for steroid 
hormones and bile acids (18). During the embryonic and fetal period, cholesterol is 
required to activate Sonic Hedgehog, a signaling protein which is essential for normal 
embryonic development (25). The rapid fetal growth and development renders the 
fetal period a high cholesterol demanding state. Cholesterol can be acquired via 
external supply (i.e. dietary intake or placental transport) or via de novo synthesis from 
acetyl-CoA which takes place mainly in the liver. Four-month old infants fed human 
milk (containing ~0.3 mM cholesterol) had significantly lower cholesterol synthesis 
rates compared to infants fed formula (containing ~0.1 mM cholesterol) (32). This 
observation underscores the notion that the de novo cholesterol synthesis rate is inversely 
related to the amount of exogenous supplied cholesterol. It has been postulated that 
alterations in cholesterol synthesis rates due to early nutrition may sustain for a 
long period (metabolic imprinting) affecting the future plasma cholesterol profile 
(20). Similar to effect of early postnatal nutrition on cholesterol synthesis, is seems 
reasonable to assume that differences in the prenatal (i.e. placental) cholesterol supply 
may affect the rate of de novo cholesterol synthesis. It has been shown previously that 
synthesis rate of cholesterol is relatively high in premature infants compared to adults 
(26). To date, the influence of intrauterine growth restriction on cholesterol synthesis 
rates is unclear. Analogous to cholesterol, fatty acids can be derived from the diet 
or can be de novo synthesized in the body. In adults on a Western type diet, de novo 
lipogenesis (DNL) is quantitatively insignificant to the total fatty acid accretion (11). 
Preterm neonates, however, are born during the physiological third term of gestation, 
i.e., when body fat accretion is highest. Preterm-born human infants may represent a 
human model of the third trimester of gestation. It is unknown whether intrauterine 
growth restriction is compensated by enhanced DNL. 
Since IUGR is linked to health consequences in early and adult life, we aimed to 
elucidate the consequences of IUGR on cholesterol and fatty acid synthesis rates. We 
also hypothesized that increased de novo synthesis of lipids contributes to the elevated 





We performed our studies in 6 SGA and 8 AGA premature neonates admitted to the 
NICU of the Beatrix Children’s Hospital in Groningen. Infants were considered SGA 
if their birth weight was at or below the 10th percentile for GA, using the Dutch 
intrauterine growth curves (15). Parenteral nutrient administration (glucose and 
amino acids) was initiated after birth according to protocol, resulting in a glucose 
intake of 3-5 mg/kg/min during the time of the experiment. To exclude possible 
influences of postnatal dietary lipid or nutrient supply on the analyses, we chose to 
determine DNL and de novo cholesterol synthesis in the first postnatal days. Before and 
during the experiment parenteral lipid emulsion was not administered and enteral 
feeding was limited (less than 20 ml/kg/day). All mothers of patients had received 
antenatal steroids, except for one.
 
experimental design
The study protocol was approved by the University Medical Center Groningen Ethical 
Committee. Written informed consent was obtained from the parents of the infants. 
The experimental protocol did not intervene with the standard treatment for this 
group of patients. Exclusion criteria were metabolic or chromosomal disorders, 
clinical suspicion of sepsis or meningitis and maternal endocrine disorders. Infants 
that were born large for gestational age (a birth weight exceeding the 90th percentile 
of the intrauterine growth curves) were excluded. The experimental set-up is depicted 
in figure 1. All infants received an intravenous infusion of [1-13C]-acetate (Isotec, 
Miamisburg, OH) at a constant rate of 0.14 mmol/kg/h during 24 hours. The start of 
the experiment (t=0) was defined by the start of the [1-13C]-acetate infusion. A blood 
sample of 1.0 ml was obtained before the start (t=0), and at the end (t=24) of the 
experiment. Blood samples of 0.4 ml were obtained at 8, 12, 16 and 20 hours after 
the start of the [1-13C]-acetate infusion. Blood samples were obtained via an intra-





birth t0h t8h t12h t16h t20h
inclusion within 
48 hours
baseline sample 1.0 ml
[1-13 C]-acetate infusion (0.14 mmol/kg/hour)
0.4 ml 0.4 ml 0.4 ml 0.4 ml
Figure 1. design of the experiment




Blood samples were collected in EDTA-containing tubes and were directly centri-
fuged for 10 min at 4000 rpm at 4°C, after which the plasma was stored at -80 ˚C 
until analysis. Commercially available kits were used for the determination of total 
cholesterol and triglycerides in plasma (Roche, Mannheim, Germany). Cholesterol 
was extracted from plasma according to Neese et al (22). Unesterified cholesterol was 
derivatized as described (26). Samples were dried under nitrogen and dissolved in 
hexane, followed by Mass Isotopomer Distribution Analysis (MIDA, described below) 
on plasma unesterified cholesterol. All analysis were performed on a Trace MS plus 
GC/MS (Interscience, Breda, the Netherlands). Derivatives were separated on a DB-
17MS 20m x 0.18mm ID (0.18μm film thickness) capillary column (Alltech, Breda, 





mass isotopomers. Plasma VLDL was isolated by density gradient ultracentrifugation 
as previously described (9). Fatty acids were extracted and derivatized as described 
earlier (23) followed by MIDA on palmitate (16:0) as the marker of fatty acid synthe-
sis. Fatty acid derivatives were analyzed by GC-MS, 5975C MSD, (Agilent Technolo-
gies, Amstelveen, The Netherlands). Fatty acids were separated on a Zebron ZB-1 30m 
x 0.25 mm ID capillary column (Phenomenex, Torrance, USA). Ions monitored were 
m/z 255-259 corresponding to the m0-m4 mass isotopomers for palmitate (C16:0). 





rected for natural abundance of 13C by multiple linear regression (17) to obtain the 




) due to incorporation of 
[1-13C]-acetate. This distribution was used in MIDA algorithms. 
Determination of cholesterol and fatty acid synthesis using Mass Isotopomer 
Distribution analysis (MIDa)
De novo synthesis of cholesterol and fatty acids was calculated by MIDA, as described 
in detail elsewhere (10, 22). In short, MIDA allows the determination of the fraction 
newly synthesized polymers like cholesterol and palmitate. In this experiment we used 
these fractions as a marker of de novo lipogenesis. Fractional cholesterol synthesis was 
calculated on regular time points (f
t
) during [1-13C] acetate infusion. We assumed that 
equation f
t
 = f∞ (1-e
-kt) is valid to describe the fractional synthesis during the infusion. 
Using the SAAM II program (SAAM Institute, Seattle, WA, U.S.A.) we estimated the 
rate constant; k (h-1) and the fractional enrichment at infinite time; f∞. To calculate 
absolute synthesis rates of cholesterol, we used the estimated total body pool size of 
free cholesterol (A) of 130 mg/kg body weight, as postulated by Neese et al.(22). The 
absolute synthesis rate of cholesterol (K) is calculated as K = k * f∞ * A. The fraction 
of newly synthesized lipoprotein palmitate at t=24 h, after cessation of the [1-13C]-
acetate infusion was calculated as described elsewhere (23). 
Statistics
All data are presented as medians and range. Statistical analyses were performed using 
SPSS 16.0 for Windows software (SPSS Inc., Chicago, OH), using the Mann-Whitney-





Table 1 shows the main characteristics of the SGA and AGA preterm neonates. 
Gestational age and postnatal age at the start of the study were similar. The median 
birth weight of the SGA neonates was 40% lower than that of the AGA neonates 
(p<0.05). The distribution of sex in both groups was not significantly different. 
Plasma concentrations of total cholesterol and of triglycerides were not significantly 
different between the SGA and AGA preterm infants.  
Intrauterine growth restriction does not affect de novo synthesis of 
cholesterol
In order to quantify the effect of IUGR on de novo cholesterol synthesis, we calculated 
the enrichment of the precursor pool acetyl-CoA for cholesterol and subsequently, 
the fractional synthesis of plasma cholesterol at subsequent time points during 
the experiment. The precursorpool enrichment remained unchanged during the 
experiment (Figure 2A) and was similar in SGA and AGA infants (Figure 3A). The 
fractional contribution of newly synthesized cholesterol rose steadily over time in 
both groups (Figure 2B) but at infinite time (f∞) there were no differences between 
SGA and AGA infants (Figure 3B). Using these curves of fractional synthesis rates, 
the rate constant of appearance of newly synthesized cholesterol k (h-1) could be 
determined. The median k-value in the SGA group [0.07 (0.05-0.10) h-1] was similar 
to that in the AGA group [0.06 (0.03-0.10] h-1, Figure 3C]. The absolute rate of 
cholesterol synthesis was calculated using the following equation: A = k * f∞ * pool 
Table 1. characteristics of preterm sGa and aGa newborns
 SGA AGA
Gestational age (wk) 29.0  (27.6-30.4) 29.5  (28.1-32.6)
birth weight (g) 903 (700-1062)* 1333 (1054-2413)
age at the start of the study (h) 24 (15-44) 22 (5-43)
plasma cholesterol (mmol/l) 1.8 (1.2-2.1) 2.1 (1.1-3.0)
plasma triglycerides (mmol/l) 0.4 (0.1-0.6) 0.5 (0.1-1.2) 
Female/male 4/2 4/4
parameters of premature sGa and aGa newborns at the start of the 
experiment. data are medians (range).  n= 6 (sGa) and 8 (aGa) neonates per group.
 *  p<0.05 sGa vs aGa. 











































Figure 2.  the enrichment of the precursorpool acetyl-coa remained in steady state from eight 
hours after infusion onward in both groups (A). (B) depicts the fractional synthesis of plasma 
unesterified cholesterol in preterm sGa (n=6; closed squares) and aGa (n=8; open circles) neonates. 
values were calculated at the indicated time points using the blood samples obtained during the 
24 h infusion of [1-13c]-acetate. curves of fractional synthesis rates were fitted using saam2 (for 
experimental details, please see materials and methods), and showed a plateau phase depicting 
fractional synthesis at infinite time (f∞) after about 50 hours. values represent the means. 
size. The calculated absolute synthesis rate of cholesterol was 26 (22-46) mg/kg/day 
in the SGA infants, similar to 20 (4-43) mg/kg/day in the AGA group (Figure 3D). 
Fractional de novo lipogenesis is increased in SGa compared to aGa 
premature newborns
To compare de novo lipid synthesis rates between SGA and AGA premature neonates, 
we performed Mass Isotopomere Distribution Analysis (MIDA) on VLDL-palmitate 
(16:0) in the obtained plasma samples. Figure 4 shows the fractional contribution 
of de novo synthesized palmitate to VLDL-palmitate after 24 hours of [1-13C] acetate 
infusion. The fraction of newly synthesized VLDL-palmitate after 24 hours of infusion 
(f-
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Figure 3. parameters of the de novo cholesterol synthesis
enrichment of the precursorpool acetyl-coa for cholesterol after 24 hours of [1-13c]-acetate infusion 
in sGa and aGa pre-terms (A). the fraction of newly synthesized unesterified cholesterol at infinite 
time, (f∞) in plasma in sGa and aGa neonates (B). Using the curves of fractional synthesis rates (Figure 
2b), the rate constant of appearance of newly synthesized cholesterol k (h-1) could be determined (C). 
the absolute rate of cholesterol synthesis was calculated using the following equation: K = k * f∞ * a 


















Figure 4. parameters of dnl.
the fraction of newly synthesized lipoprotein palmitate after 24 hours of infusion (f-24) in sGa and 
aGa preterm infants. values represent the median and range. n= 6 (sGa) and 8 (aGa) per group. 
*p<0.05 sGa vs. aGa preterm infants.




Exposure to an adverse fetal environment may permanently alter the structure, function 
or metabolism of major tissues or organs, herewith increasing the susceptibility to 
diseases later in life (1). Metabolic consequences of IUGR have been recognized 
and immediate and long-term effects of IUGR, resulting in SGA, on plasma lipid 
levels are reported (30). We determined the influence of IUGR on de novo synthesis 
rates of cholesterol and fatty acids in SGA and AGA preterm neonates as an indicator 
of intrauterine lipogenesis. We demonstrated similar synthesis rates of cholesterol 
whereas fractional hepatic palmitate synthesis was increased in SGA compared to AGA 
preterm infants.
DNL, as reflected by the fraction of VLDL-palmitate that was newly synthesized after 
24 h of [1-13C]-acetate infusion, was ~50% higher in SGA than in AGA infants. 
Although this difference is substantial the clinical relevance of this change in DNL 
regarding plasma TG levels needs to be established. We speculate that this relevance 
may be limited considering the relatively low fractions of hepatic DNL in VLDL-
palmitate in SGA and AGA neonates. Moreover plasma concentrations of triglycerides 
were comparably low in both groups, excluding any substantial effect of enhanced 
DNL. We cannot exclude, however, a relevant effect of the mildly increased DNL to 
the longer term fat accretion in SGA neonates.  We did not confirm the higher levels 
of triglycerides in the SGA infant as reported by others (30). Wang et al demonstrated 
significantly higher plasma concentrations of TG, TC and LDL-c in SGA neonates 
compared to AGA neonates, either when born preterm or term, in the first days 
after birth. The plasma TG concentrations determined in our study were generally 
lower (~0.5 mM) compared to TG concentrations reported by Wang et al (~ 2.3 and 
1.5 mM in respectively SGA and AGA neonates) whereas TC levels between the two 
studies were within the same range (~2 mM). A possible explanation for the lower 
plasma triglyceride levels in the present study could be related to differences in the 
use of intravenous lipid emulsions and enteral nutrition. In our present study, the 
neonates did not receive parenteral lipids and only limited amounts of enteral feeding 
(< 20 ml/kg/day). In support of this possibility, plasma triglyceride concentrations 
measured in the present study are in line with concentrations found in cord blood 
samples of preterm and term infants (7), and with serum triglyceride concentrations 
in premature infants within the first day after birth (6). In the present study, hepatic 
de novo lipogenesis was increased in the SGA group whereas plasma TG concentrations 
were similar in both groups. Apparently, plasma triglyceride levels are not strongly 
correlated to DNL. 
Since cholesterol is indispensible for normal fetal development, adequate supply to 
the fetus needs to be warranted during gestation. Both placental and fetal human 
tissues are capable of de novo cholesterol synthesis (4). Several observations support 
the notion that cholesterol is transported from mother to fetus (28, 33, 21). Fetal 
growth depends on adequate maternal-fetal transport of nutrients. Factors that impair 
fetal nutrional supply, such as maternal undernutrition or placenta insufficiency are 
associated to perturbed cholesterol metabolism in adulthood. We hypothesized that 
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IUGR in humans could influence fetal cholesterol synthesis rates, thereby altering the 
‘metabolic set point’ and influence future response to dietary cholesterol. The present 
study in preterm neonates, using undisputed stable isotope methodologies, shows 
that IUGR does not generate effects on endogenous synthesis rates of cholesterol or 
on plasma cholesterol concentrations. 
Our results on cholesterol synthesis rates are in the same range with results by others 
using MIDA in preterm neonates (26) and deuterium incorporation techniques in 
older infants (3, 5, 32). 
An advantage of the presently used MIDA method is that it allows for the use of small 
blood samples. The alternative method, based on deuterium incorporation into newly 
synthesized lipids, required substantially larger blood samples of 8 ml (3, 32). Previ-
ously, the deuterium method was used in infants of four to five months of age, but 
this scale of blood sampling is definitively not applicable to the currently studied 
population. 
In summary, we conclude that intrauterine growth restriction does not influence 
the synthesis rate of cholesterol whereas it increased the de novo fatty acid synthesis. 
Our results indicate that the neonatal plasma concentration of triglycerides does not 
strongly depend on the de novo fatty acid synthesis rate. The present results do not sup-
port the notion that IUGR exerts major effects on lipid metabolism within the time 
frame studied. 
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FETAL LIVER X RECEPTOR 
ACTIVATION ACUTELy 
INDUCES LIPOGENESIS, 
BUT DOES NOT AFFECT 
PLASMA LIPID RESPONSE 


















There is increasing evidence that the metabolic state of the mother during pregnancy 
affects long-term glucose and lipid metabolism of the offspring. The Liver X Recep-
tors (LXR) α and β are key regulators of cholesterol, fatty acid and glucose metabo-
lism. LXRs are activated by oxysterols and expressed in fetal mouse liver from day 
10 of gestation onwards. In the present study, we aimed to elucidate whether in utero 
pharmacological activation of LXR would influence fetal fatty acid and glucose me-
tabolism and whether this would affect lipid homeostasis at adult age. 
Methods and results
Exposure of pregnant mice to the synthetic LXR agonist T0901317 increased hepatic 
mRNA expression levels of Lxr target genes and hepatic and plasma triglyceride lev-
els in fetuses and dams. T0901317 treatment increased absolute de novo synthesis and 
chain elongation of hepatic oleic acid in dams and fetuses. T0901317 exposure in 
utero influenced lipid metabolism in adulthood in a gender specific manner: hepatic 
triglyceride content was increased (+45%) in male offspring and decreased in female 
offspring (-42%) when fed a regular chow diet, compared with untreated gender 
controls. Plasma and hepatic lipid contents and hepatic gene expression patterns in 
adult male or female mice fed a high fat diet were not affected by T0901317 pretreat-
ment. 
Conclusion
We conclude that LXR treatment of pregnant mice induces immediate effects on lipid 
metabolism in dams and fetuses. Despite the profound changes during fetal life, long-
term effects appeared to be rather mild and gender selective without modulating the 
lipid response to a high-fat diet.




In humans, the nutritional condition during pregnancy has been shown to have a 
persistent effect on aspects of lipid and carbohydrate metabolism of the developing 
fetus. Maternal overnutrition leads to a higher incidence of insulin resistance, obesity, 
hypertension and cardiovascular diseases in adult offspring (6). Effects of a high-fat 
maternal diet during pregnancy on long-term health status of the offspring are rela-
tively well-studied in animal models (3). However, relatively little is known about 
long-term consequences of targeted alterations in fetal lipid metabolism in utero.
The Liver X Receptors have been identified as key players in the regulation of choles-
terol, fatty acid and carbohydrate metabolism in adult mammals. Liver X Receptors 
LXRα (NR1H3) and LXRβ (NR1H2) are members of the nuclear receptor superfamily 
of ligand-activated receptors. Both LXR isoforms are activated by oxidized cholesterol 
metabolites (oxysterols) with no LXRα/β specificity documented (20). Expression 
of LXRα is mainly restricted to liver, intestine, adipose tissue and macrophages, while 
LXRβ is broadly expressed (23). Activated LXRs heterodimerize with ligand-activated 
Retinoid X receptor (RXR) at LXR response elements present in the promotors of 
target genes to induce their transcription. Activation of LXRs induces expression of 
the sterol regulatory element binding protein 1c (SREBP1c) that subsequently activates 
the lipogenic genes acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN) and 
stearoyl-Coenzyme A desaturase 1 (SCD1) (29). It has been postulated that activation 
of LXR could induce carbohydrate response element-binding protein (ChREBP) and 
in this way indirectly influence glycolysis via influencing expression of liver-specific 
pyruvate kinase (PKLR) (7). 
Expression of Lxra and Lxrb has been demonstrated in mouse fetuses from day 11.5 post 
coitum onwards (2), however, the functional role of LXRs during fetal development 
and in the newborn has not been defined. LXR does not appear to be essential for 
normal fetal development as mice with targeted inactivation of Lxra-, Lxrb-, or Lxra/b 
(1, 17, 21) show normal fetal development.
Mechanisms by which fetal and early postnatal environment influence lipid and glu-
cose homeostasis in adult life are poorly defined. We previously showed that treatment 
of pregnant mice with the widely used LXR agonist T0901317 affects cholesterol me-
tabolism in the fetus. T0901317 treatment of pregnant mice activated LXR in the fe-
tuses, resulting in induction of genes involved in fetal cholesterol metabolism. Inter-
estingly, the treatment did not profoundly influence cholesterol metabolism at adult 
age (27, 27). To delineate the functional importance of LXRs in control of fetal fatty 
acid and carbohydrate metabolism, we supplemented the diet of pregnant mice with 
T0901317. In the present study we aimed 1. to determine whether pharmacological 
activation of Lxr in fetuses through maternal treatment with T0901317 activated Lxra 
or Lxrb in the fetal liver and influenced fetal fatty acid and glucose metabolism; and 2. 
to assess whether Lxr activation during fetal development changed lipid homeostasis 
into adulthood, when weaned onto standard chow or on a high-fat diet. Our results 
indicate that maternal T0901317 treatment activates Lxrs and strongly affects lipid 
metabolism in the fetus. The prenatal treatment only had relatively minor, gender-
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selective effects on lipid homeostasis in (young) adulthood and did not influence the 
response to a short-term high-fat diet.
MATERIALS AND METHODS
animals
Animals were housed in temperature-controlled rooms (23 °C) with 12 hours light 
cycling and received standard RMH-B mouse chow (Arie Blok BV, Woerden, The 
Netherlands) and water ad libitum. Pregnant C57BL/6J mice were obtained from Har-
lan (Horst, The Netherlands) at 2 days post coitum (dpc). Lxra+/- female mice (25) on 
a C57BL/6J background were crossed with Lxra+/- male mice on the same background 
in our laboratory to obtain offspring with Lxra+/+, Lxra+/- and Lxra-/- genotypes as previ-
ously described (27). All experimental procedures were approved by the local Ethical 
Committee for Animal Experiments of the University of Groningen.
experimental procedures
From day 10 post coitum until day one after delivery, C57BL/6J wild-type females re-
ceived standard chow only or chow supplemented with 0.015% w/w T0901317 
(Cayman Chemicals, Ann Arbor, Michigan), as described in (26). At days 13.5, 15.5, 
17.5 and 19.5 post coitum pregnant C57BL/6J mice were anaesthetized with isoflurane 
and terminated by heart puncture. Lxra+/- females received the T0901317 diet from 
day 10 pc till day 19.5 pc and were terminated at day 19.5 pc. Blood was collected in 
EDTA containing tubes. Liver samples of the dams were snap-frozen in liquid nitro-
gen. Fetuses were removed from uteri, their weight and length were measured, and 
they were terminated by decapitation and dissected. Pups were sacrificed at day 1 
post partum. Blood samples were taken by exsanguisation. Livers and intestines of fe-
tuses and pups were collected, immediately snap-frozen in liquid nitrogen and stored 
at -80 °C until mRNA isolation or biochemical analysis. Samples for microscopic 
evaluation were snap-frozen in liquid nitrogen for Oil-Red-O staining. Pups were 
genotyped by PCR using allele-specific primers (wild-type: sense 5’-CACCCATTCTC-
CCGTGCTTCTCTT G-3’; knockout: sense, 5’-GGGCCAGCTCATTCCTCCCACTCAT-3’; 
antisense for both, 5’-GTTTCTCTCCCCTATCTAGGGAGAC-3’).
To investigate lipogenesis and chain elongation of several fatty acids in the liver, a 
separate group of pregnant females on chow or on chow with T0901317 received 
these diets with 10 mg/g [1-13C] acetate (Isotec, Miamisburg, OH, USA) added from 
day 17.5 of gestation till day 19.5 pc and were terminated at 19.5 pc.
To investigate the influence of receiving T0901317 during fetal development on cop-
ing with a high fat/high cholesterol diet at adult age, pregnant C57BL/6J females 
received chow only or chow supplemented with 0.015% w/w T0901317 from day 
10 of gestation until day 1 after delivery. All dams received chow till the pups were 
weaned. Offspring received chow until 6 weeks of age and received either chow or 
a semi-synthetic Western-type diet (HFHC) containing 15% (w/w) cacao butter and 
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0.25% (w/w) cholesterol (Diet W; Special Diet Services, Witham, UK) for two weeks. 
Offspring was terminated at 8 weeks of age.
analytical procedures
Liver homogenates were made by homogenization of the complete fetal liver or 
(approximately 20-80 mg, depending on age) in 200 μL ice-cold water. Hepatic 
lipids were extracted using the Bligh and Dyer method (4). Pooled plasma samples 
from all animals of one group were used for lipoprotein separation by fast protein 
liquid chromatography (FPLC) as described previously (28). Commercially available 
kits were used for the determination of triglycerides in liver extracts, plasma samples 
and FPLC fractions (Roche, Mannheim, Germany).
Determination of fatty acid synthesis using MIDa
MIDA allows quantitation of the biosynthesis of polymers in vivo and is described in 
detail elsewhere (13). Hepatic lipids from mothers and their fetuses receiving [1-13C] 
acetate were extracted and hydrolyzed by adding 0.5 ml 0.5M HCl in acetonitril and 
heating for 45 minutes at 100° C. As an internal standard, 100 ul or 5 ul of C17:0 (0.5 
mg/ mL) in chloroform was added to the mother and fetal liver extracts, respectively. 
Fatty acids were extracted by adding 1,5 ml hexane, 5 minutes shaking and centrifu-
gation for 5 minutes at 2500 rpm. The organic phase was transferred to a clean tube, 
and samples were dried down at 40° C under N
2
. Samples were derivatized for 15 
minutes at RT using 50 ul of 1: 2: 6 pentafluorobenzyl: triethanolamine: acetonitril 
solution. 0.5 ml 0.1 M HCl was added and the derivatives were extracted using 1 ml 
hexane, 5 minutes shaking and 5 minutes centrifugation at 2500 rpm after which the 
organic phase was transferred to a GC-MS vial. Enrichments of the PFB-derivatives 
of hepatic fatty acids were measured by gas chromatography-mass spectrometry. De-
rivatives were separated on a Zebron ZB-1 30 m x 0.25 mm ID (0.25 μm film thick-
ness) capillary column (Phenomenex, Torrance, USA). The oven temperature started 
at 100° C for 1 min, increased to  200° C at a rate of 50° C/min, then increased to 
270° C at a rate of 5° C/min, and finally increased to 300° C at a rate of 50° C/min, 
and remained at 300° C for 4 minutes. Mass spectrometry analysis was performed by 
electron capture negative ionization (ECNI) with methane as a moderating gas. The 
ion monitored were m/z 255-259 corresponding to the m0-m4 mass isotopomers 
for C16:0, m/z 269-273 for C17:0, m/z 283-287 for C18:0 and m/z 281-285 for 
C18:1ω9. Calculations on the newly synthesized polymers, the isotope enrichments 
of their monomer precursor (acetyl-CoA), and synthesis and chain-elongation of 
stearic acid and oleic acid are described elsewhere (19, 22).
rNa isolation and PCr procedures
Total RNA was extracted from frozen tissues with TriReagent (Sigma, St. Louis, MO, 
USA) and quantified using a NanoDrop ND1000 spectrophotometer (NanoDrop 
Tech nologies Inc., Wilmington, DE, USA). cDNA synthesis and real-time quantitative 
PCR were performed as described by Plösch et al (21). Primer and probe sequences 
for 18S, Srebp1c, Acc1, Fasn, Gk, G6p, Pck1, Pk (12), Scd1 (25), Fxr, Ppara (15), Lxra, Lxrb 
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(27), have been published, with the exception of Rxra, sense 5’-GGCAAACATGGGGC-
TGAAC -3’; antisense 5’- GCTTGTCTGCTGCTTGACAGAT -3’; and probe 5’- CCA-
GCTCACCAAATGACCCTGTTACCAAC -3’ (accession number NM_011305), Insr, 
sense 5’- TGAGTCAGCCAGTCTTCGAGAA -3’; antisense 5’-ACTACCAGCAT TGG CT-
GTCCTT- 3’; and probe 5’- CTGCCAT CATGTGGTCCGCCTTCT -3’ (accession number 
NM_010568). Expression levels were normalized to those of 18S ribosomal RNA. 
18S rRNA was analyzed in separate runs and not found significantly different between 
the experimental groups.  
histology
Liver histology was examined on frozen liver sections after Oil-Red-O staining for 
neutral lipids by standard procedures.
Statistics
Statistical analyses were performed using SPSS 14.0 for Windows (SPSS Inc., Chicago, 
USA). Differences between the groups were analyzed by Kruskal Wallis test followed 
by Mann-Whitney-U-test. Data presented are means ± SD. A p-value smaller than 0.05 
was considered to be statistically significant. 
RESULTS
t0901317 treatment to dams strongly induces genes involved in lipogenesis in 
dams and fetuses and acts mainly via Lxra
As described previously, dams receiving T0901317 from 10.5 dpc to 19.5 dpc had 
slightly lower body weights on day 19.5 of gestation compared to control dams (26). 
Liver weights of the treated dams, expressed as a percentage of total body weight, were 
increased by ~50% during the entire treatment period. Body weight of the fetuses on 
day 13.5, 15.5, and 17.5 pc was not influenced by T0901317 administration; only 
on day 19.5 it was slightly reduced in the treated animals (26).  T0901317 treatment 
had no influence on the number of offspring per dam or on their body weights (1.26 
± 0.19 vs. 1.38 ± 0.13 g in treated and untreated animals, respectively, at day 1 after 
birth) (26).
Our first aim was to establish whether T0901317 treatment of the wild-type dams 
affects gene expression levels of lipogenic Lxr target genes in dams and fetuses. 
In dams (Suppl. Figure 1a to c) and in fetuses (Figure 1a to d), administration of 
T0901317 strongly increased hepatic mRNA levels of Srebp1c¸ Fasn and Scd1 compared 
to controls. Acc1 induction in the fetus was less pronounced by T0901317 treatment. 
Administration of T0901317 to pregnant mice did not significantly affect expression 
levels of nuclear receptors Rxra, Ppara or Fxr in the fetal liver (Suppl. Figure 2a to c).
To ascertain to what extent T0901317-induced effects on lipid metabolism were Lxrα 
or -β mediated, Lxra+/- females were crossed with Lxra+/- males. T0901317 treat ment 
to the heterozygous dams resulted in significantly lower expression levels of lipogenic 
LXR induces lipogenesis in utero
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LXR target genes (Srepb1c, Fasn) in the liver of Lxra knockout fetuses than in wild-type 
fetuses (Figure 2a and 2b), indicating that the observed effects are, at least partly, 
mediated via an Lxr alpha-specific effect. 






































































post partumDays post coitum
Figure 1. changes in relative hepatic gene expression of fetuses on several days of gestation upon 
treatment of the dam with t0901317. expression of fetal (A) Srebp1c, (B) Acc1, (C) Fasn, and (D) Scd1. 
results were normalized to 18s mrna levels. adult expression levels are arbitrarily defined as 1. black 
bars, control fetuses; open bars, fetuses from dams receiving 0.015% t0901317. values represent the 
mean ± sd. n=6 dams per group; *, p < 0.05 for treated vs control.
Figure 2

















































Figure 2. changes in relative hepatic gene expression in wild type and lxrα-knockout fetuses at day 
19.5 of gestation upon treatment of the heterozygote dam with t0901317. Hepatic expression levels 
of fetal (A) Srebp1c and 
(B) Fasn are displayed. results were normalized to 18s mrna levels. adult expression levels are 
arbitrarily defined as 1. values represent the mean ± sd. n=6 dams per group, with an average of 5 
fetuses per dam; #, p < 0.05 for treated vs control, *, p < 0.05 for knockout vs wild type.
Figure 2



















































t0901317 administration induces transient hepatic steatosis in pregnant mice 
and their fetuses
T0901317 treatment increased hepatic triglyceride content ~ 4-fold in pregnant 
females after three days of treatment (Figure 3a). This effect gradually declined 
during gestation, but was still apparent at the time of delivery. T0901317 treatment 
decreased plasma triglyceride concentrations in dams, but only during the pregnancy 
(Figure 3b). FPLC analysis of maternal plasma at day 19 of gestation revealed that the 
reduction in trigly cerides in the T0901317-treated dams was mainly in VLDL-sized 
fractions (Figure 3c). 
Maternal T0901317 treatment increased hepatic triglyceride concentrations in the 
fetuses (Figure 4a). At day one after delivery, however, triglyceride concentrations in 
livers of T091317-exposed pups remained at (induced) fetal level, whereas concentra-
tions in control pups surged. Fetal plasma triglyceride concentrations, measurable at 
19.5 dpc and at day 1 after delivery, were significantly elevated upon LXR activation 
(Figure 4b). Both in the control and in the T0901317-exposed pups, plasma lipid 
levels strongly increased after delivery. FPLC analysis showed a profile typical for fetal 
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post partumDays post coitum
Figure 3. (A) Hepatic and (B) plasma triglyceride levels on several days of the gestation of dams, 
and (C) triglyceride levels in Fplc samples of pooled plasma (n=6 per group) of dams at day 19 of 
gestation. black bars or black line, control mice; open bars or dotted line, mice receiving 0.015% 
t0901317 in the diet. values represent the mean ± sd. n=6 dams per group; *, p < 0.05 for treated vs 
control.

































































































post partumDays post coitum
Figure 4. (A) Hepatic and (B) plasma and triglyceride levels on several days of the gestation of 
fetuses. (C) triglyceride levels in Fplc samples of pooled plasma (n=20 per group) of 19 dpc fetuses. 
(D) Hepatic triglyceride concentrations in wild type and Lxr knockout fetuses on day 19 of gestation 
upon treatment of the heterozygote mother with t0901317. black bars or black line, control mice; 
open bars or dotted line, mice receiving 0.015% t0901317 in the diet. values represent the mean ± 
sd. n=6 dams per group; *, p < 0.05 for treated vs control.
murine plasma and revealed that the increase in plasma TG reflects elevated IDL/LDL 
levels (Figure 4c). Consistent with gene expression data, in Lxra knockout fetuses 
T0901317 administration increased hepatic triglyceride concentrations to a lower 
extent compared to wild type fetuses (~70% vs. ~150%, respectively; each p <0.01; 
Figure 4d). Oil-Red-O staining for neutral lipids confirmed lipid accumulation in 
treated wild-type pups at day 13.5, 15.5, 17.5 and 19.5 of gestation and at day one 
after delivery. Livers of control and T0901317-treated wild-type fetuses on day 17.5 
and day one after delivery are shown in Figure 5a to d). 
t0901317 treatment increases absolute synthesis and total pool of oleate in 
pregnant dams and fetuses on e19.5
Using a 13C-acetate method, we quantified to what extent T0901317 treatment affected 
the de novo hepatic synthesis of palmitate, stearate and oleate and the hepatic pool size 
of these fatty acids in dams and fetuses. T0901317 treatment increased total de novo 
synthesis and chain elongation of oleate (C18:1) in dams and fetuses at day 19.5 of 







Figure 5. oil-red-o (oro) staining for neutral fat in developing fetal liver on several days of 
gestation upon treatment of the mother with t0901317. no staining was observed in liver sections 
from fetuses from dams receiving the control diet (A, 17.5dpc and C, 1dpp, respectively). oil-red-o 
staining was found in liver sections from fetuses from dams treated with t0901317 (B, 17.5 dpc and D, 
1 day post partum, respectively). original magnification 20x.
stearate (C18:0) synthesis. Chain elongation of stearate was reduced in treated fetuses. 
In dams, T0901317 administration increased the total hepatic pool of oleate and it 
increased both the oleate and the palmitate pool in fetuses (Figure 6c and d).
In utero Lxr activation does not influence basal insulin signaling
To test the hypothesis that Lxr activation influences carbohydrate metabolism in the 
wild-type mouse, via induction of gene expression of Srebp1c and Chrebp and their 
subsequent target genes, we measured hepatic expression levels of several genes in-
volved in carbohydrate metabolism in fetuses from untreated and treated wild-type 
dams. Treat ment of dams with T0901317 had no influence on hepatic gene expres-
sion levels of G6pc, Pck1, Gck, Chrebp, Pklr or Insr in the fetuses (Suppl. Fig 3a to f). Since 
gene expression levels do not necessarily reflect physiological changes, we examined 
whether T0901317 treatment influenced insulin signaling in offspring. We performed 
an adapted insulin tolerance test in 1-day old pups of treated and untreated dams. In-
traperitoneal injection of 1-day old pups with 0.75U/kg insulin lowered blood glu-
cose levels by 50% compared to pups injected with saline. Prenatal T0901317 treat-
ment of the dams did not influence this insulin response, compared with controls.
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Long-term effects of prenatal Lxr activation in offspring into adulthood
We determined whether T0901317 treatment of the dam had long-lasting effects in 
the fetuses, i.e., into adulthood. Previous studies have indicated that a perinatal pro-
gramming phenotype may only become apparent in adulthood upon exposure to a 
metabolic challenge. We administered T0901317 from day 10 of gestation until day 
1 after delivery to C57BL/6J females via the diet (0.015% w/w in chow). Nest sizes 
were comparable in the two treatment groups, with an average of 6 pups per nest. 
After weaning, offspring received chow until 6 weeks of age; subsequently, offspring 
received either chow or a semi-synthetic Western-type diet (HFHC) containing 15% 
(w/w) cacao butter and 0.25% (w/w) cholesterol for two weeks. 





























































































Figure 6.  absolute de novo lipogenesis and chain elongation, and total pool size of several fatty 
acids in livers of dams and fetuses at day 19 of gestation. (A) absolute synthesis in dams; (B) absolute 
synthesis in fetuses; (C) total pool of fatty acids in dams; (D) total pool of fatty acids in fetuses. c16:0 
(palmitate), c18:0 (stearate) and c18:1 (oleate) fractions were analyzed and calculated as described 
in the materials and methods section. black bars: de novo lipogenesis in control animals; open bars: 
de novo lipogenesis in t0901317 treated animals; dark grey bars: chain elongation in control animals; 
light grey bars: chain elongation in t0901317-treated animals. values represent the mean ± sd. n=4 
fetuses from 3 dams in the t0901317-treated group; n=4 fetuses from 8 dams in the control group; #, 
p < 0.05 for total new synthesis (a and b) or total pool (c and d) in treated animals versus controls; 
*, p < 0.05 for de novo lipogenesis in treated animals versus controls; $, p < 0.05 for chain elongation 
in treated animals versus controls.
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(27) and was similar in all male and in all female offspring. In chow-fed offspring, 
gene expression levels of Srebp1c, Fasn and Scd1 were not different between pre-
treated and untreated male offspring on control diet (Figure 7a). Control-fed females 
from T0901317-treated dams however, showed lower Fasn expression levels (-30%) 
compared to untreated females (Figure 7b). Male offspring on control diet from 
treated dams had ~42% higher hepatic triglyceride levels than male offspring on 
control diet from untreated dams, while female offspring on control diet from treated 
dams had ~42% lower hepatic triglyceride levels than female offspring on control diet 
from untreated dams (Table 1). Plasma triglycerides in male and females were not 
influenced by T0901317 pretreatment (Table 1), although FPLC analysis showed that 
control male offspring receiving CON diet had slightly higher VLDL levels than other 
male offspring groups (Figure 7c). No change in triglyceride FPLC profiles was seen 
































































































Figure 7. changes in relative hepatic gene expression in offspring of mice fed chow containing 
0.015% t0901317 or control chow during gestation, and Fplc profiles of this offspring. the offspring 
received either chow or a high fat/high cholesterol diet from 6 till 8 weeks of age. (A) Gene 
expression in male offspring, (B) gene expression in female offspring. (C) Fplc profile of male 
offspring, (D) Fplc profile of female offspring. open bars and black lines: control offspring of control 
mice, light shaded bars and black dotted line: high fat/high cholesterol offspring of control mice; dark 
shaded bars and grey lines: control offspring of t0901317-fed mice; black bars and grey dotted lines: 
high fat/high cholesterol offspring of t0901317-fed mice. values represent the mean ± sd. n=6; 
* p < 0.05 for high fat vs control, #, p < 0.05 for t0901317 vs control during gestation.
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The high-fat diet increased hepatic gene expression levels of the lipogenic LXR target 
genes Srebp1c and Scd1 in all male and female offspring, regardless of exposure to 
T0901317 during gestation (Figure 7a and b). Interestingly, a gender specificity was 
observed concerning Fasn expression. Fasn expression levels were significantly higher in 
high-fat male offspring from untreated dams compared to control-fed male offspring 
from untreated dams (+200%, p=0.017), while Fasn expression levels were not upregu­
lated by the high fat diet in pretreated male offspring compared to pretreated control 
males (p=0.247). Similarly, females pretreated with T0901317 showed no upregulation 
of Fasn upon receiving the high fat diet. In all male offspring, hepatic triglyceride 
levels were increased in animals that received the high fat diet, independent from pre-
treatment with T0901317 (Table 1). The high fat diet did not lead to higher hepatic 
triglyceride levels in female offspring. Feeding the high fat diet did not significantly 
change plasma triglyceride levels or FPLC profiles in either males or females from 
chow-fed or T0901317-fed dams (Table 1, Figure 7b and c).
 
Table 1. parameters of adult offspring
              Hepatic TG (umol/g)              Plasma TG (mM)
Control T0901317 Control T0901317
m con 2.4 ± 0.6 3.4 ± 1.0 # 0.43 ± 0.08 0.34 ± 0.17
m HFHc 6.6 ± 1.2 * 6.7 ± 2.1 * 0.35 ± 0.15 0.33 ± 0.13
F con 11.1 ± 2.3 6.4 ± 2.9 # 0.21 ± 0.05 0.25 ± 0.08
F HFHc 11.6 ± 4.5 9.5 ± 2.0 0.26 ± 0.11 0.19 ± 0.05
parameters of c57bl/6J olaHsd offspring of mothers that received either chow or chow 
supplemented with 0.015% t0901317. the offspring received either chow or a high fat/high 
cholesterol diet from 6 till 8 weeks of age. data are mean ± sd. n=6; *, p<0.05 HF/Hc vs con #, 




We previously showed that targeted treatment of pregnant mice with the synthetic 
LXR agonist T0901317 activates Lxr in the fetuses. In the present paper, we inves-
tigated whether in utero Lxr activation by T0901317 changes fatty acid and glucose 
metabolism in the fetus and in adult offspring. Our data show that this treatment 
results in acute effects on lipid homeostasis in dams and fetuses, but not on glucose 
homeostasis in fetuses, and in relatively minor but persistent consequences on fatty 
acid metabolism during adulthood.
Supplementation of the diet of the dam with T0901317 induced LXR target genes 
Srebp1c, Acc1, Fasn, and Scd1 in the fetal liver, suggesting that T0901317 is transport-
ed across the placenta activates Lxr. We previously showed that maternal T0901317 
admini stration did not influence fetal hepatic gene expression levels of Lxra or b (27). 
Our present results in Lxra knockout fetuses show that hepatic Lxr effects are mainly 
caused by Lxra and that Lxrb compensates about 50% of Lxr action in the absence of 
Lxra.
Lxr-specific effects on lipid metabolism in the mother and in the fetus are compa rable 
to the effects seen in non-pregnant adult mice (21, 24). T0901317 administration 
increased hepatic triglyceride levels in dams, which was similar to studies in adult 
male mice (12, 14). Hepatic triglyceride accumulation decreased during gestation 
in treated dams, possi bly by increased transport from the liver, either to other tissues 
or to the rapidly growing fetus. The hepatic lipid concentrations in one-day old pups 
varied considerably within one group. Possibly, this is caused by the variation in feed-
ing time of the pups. Prolonged fasting leads to hepatic lipid accumulation (26). Be-
cause we could not control the breast feeding times by the mother, some pups could 
have been fasted for a longer time than other pups, leading to higher liver triglyceride 
concentrations compared to pups that were fed prior to termination. 
Grefhorst et al. found no difference in plasma triglycerides in wild-type male mice 
treated with T0901317 compared to controls (11). T0901317 treated dams showed 
a lower ing of plasma triglycerides compared to controls, representing a decrease in 
VLDL levels. Since plasma triglycerides in fetuses and pups from treated dams were 
increased, this seems to imply that treated dams transfer more lipid to the fetus com-
pared to controls. Further studies have to elucidate how LXR activation influences 
lipid transport to the fetus.
Treated dams and fetuses showed an increase in absolute hepatic synthesis of oleic 
acid. Based on the 13C-acetate method used and the absence of increased palmitate 
and stearate synthesis, we interprete that this observation is due to increased palmitate 
elon gation and subsequent desaturation by stearoyl-coenzyme A desaturase 1 (Scd1). 
Scd1 catalyzes the synthesis of monounsaturated fatty acids from saturated fatty acids 
(10, 10)). Scd1 is a target gene of Lxr, and its expression was increased in maternal 
and fetal liver upon T0901317 exposure.
Apart from the well-characterized role of Lxr in cholesterol metabolism, a potential 
role controlling glucose homeostasis via activation of  Srebp1c and Chrebp has been 
suggested (9, 16), although this role remains controversial (8, 18). Using an adapted 
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insulin toler ance test in 1-day old pups, no effect of the T0901317 pre-treatment was 
found on glucose levels. Our results show that Lxr activation did not quantitatively 
influence the hepatic expression of any of the tested genes related to glucose metabo-
lism in the fetus. 
We next investigated whether Lxr activation by T0901317, which induced profound 
changes in lipid metabolism in perinatal life, also had long-lasting effects in lipid 
homeo stasis, i.e. into adulthood. Female chow-fed offspring from T0901317-treated 
dams showed lower Fasn expression levels and lower hepatic triglyceride levels com-
pared to untreated chow-fed female offspring. Strikingly, although no changes were 
seen on gene expression levels, in the male chow-fed offspring hepatic triglyceride 
levels were higher than in untreated chow-fed male offspring. Apparently, treatment 
with T0901317 in utero reduces hepatic storage of triglycerides in female offspring 
while it induces hepatic storage of triglycerides in male offspring.
The subtle changes in adult lipid metabolism caused by in utero Lxr activation could 
be enlarged by receiving a high-fat diet at adult age. As expected (5), short term 
(two weeks) high fat feeding led to higher expression levels of lipogenic genes in 
all offspring and higher hepatic triglyceride levels in male offspring. However, these 
effects were regard less of in utero treatment with T0901317. Apparently, receiving a 
high-fat diet for two weeks only eliminates rather than increases the gender-specific 
effects caused by in utero Lxr activation. Based on this observation it is tempting to 
speculate that long-term high-fat feeding would possibly override the relatively small 
effects of the prenatal treatment.
We conclude that Lxr activation by T0901317 treatment of pregnant mice induces 
immediate effects on lipid metabolism in dams and fetuses, including increases in 
fatty acid synthesis and triglyceride levels. Lxr activation did not significantly influence 
expression of carbohydrate metabolism related genes, nor the glucose response to 
insulin administra tion. Despite profound changes in lipid metabolism during fetal 
life, long-term effects on lipid metabolism appear to be rather mild, and not related 
to the lipid response to a high-fat diet.
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Supplemental Figure 1. changes in relative hepatic gene expression in genes encoding proteins 
involved in de novo lipogenesis in c57bl/6 dams on several days of gestation upon treatment of 
the dam with t0901317. expression of maternal hepatic (A) Srebp1c, (B) Fasn, and (C) Scd1. results 
were normalized to 18s mrna levels. black bars, control dams; open bars, dams receiving 0.015% 
t0901317. values represent the mean ± sd. n=6; *, p < 0.05 for treated vs control.
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Supplemental Figure 2. changes in relative hepatic gene expression in c57bl/6 fetuses on several 
days of gestation upon treatment of the dam with t0901317. Hepatic expression levels of fetal 
(A) Rxra, (B) PPARa and (C) Fxr are displayed. results were normalized to 18s mrna levels. adult 
expression levels are arbitrarily defined as 1. black bars, control fetuses; open bars, fetuses from 
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Supplemental Figure 3. Hepatic gene expression of proteins involved in glucose metabolism in 
c57bl/6 fetuses on several days of gestation upon treatment of the dam with t0901317. Hepatic 
expression levels of fetal (A) G6pc, (B) Pck1, (C) Gck, (D) Chrebp, (E) Pklr and (F) Insr are displayed. 
adult expression levels are arbitrarily defined as 1. black bars, control fetuses; open bars, fetuses 
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Background and aim 
Human milk contains prebiotic oligosaccharides which stimulate the growth of in-
testinal bifidobacteria and lactobacilli. It is unclear whether the prebiotic capacity 
of human milk contributes to the larger bile salt pool size and the more efficient fat 
absorption in infants fed human milk compared to formula. We determined the effect 
of prebiotic oligosaccharides on bile salt metabolism in rats. 
Methods and results 
Rats were fed a control diet, or an isocaloric diet containing a mixture of galactoo-
ligosaccharides (GOS), long chain fructooligosaccharides (lcFOS) and acidified oli-
gosaccharides (AOS) for 3 wk. We determined synthesis rate, pool size and fractional 
turnover rate (FTR) of the primary bile salt cholate using stable isotope dilution 
methodology. We quantified bile flow and biliary bile salt secretion rates through bile 
canulation. Prebiotic intervention resulted in significant changes in fecal and colonic 
flora: the proportion of lactobacilli increased with 344% (p<0.01) in colon content 
and with 139% (p<0.01) in feces compared to the control group. The number of 
bifidobacteria also increased with 366% (p<0.01) in colon content and with 282% 
in feces after the prebiotic treatment. Furthermore, pH in both colon and feces de-
creased significantly with 1.0 and 0.5 pH point, respectively. However, despite this 
alteration of intestinal bacterial flora, no significant effect on relevant parameters of 
bile salt metabolism and cholate kinetics was found. 
Conclusion 
The present data in rats do not support the hypothesis that prebiotics naturally 
present in human milk contribute to a larger bile salt pool size or altered bile salt 
pool kinetics. 




The enterohepatic circulation of bile salts, the major constituents of bile, serves two 
important functions in the human body. Bile salts enhance the absorption of long 
chain saturated fatty acids and fat-soluble vitamins from the intestine. Furthermore, 
the enterohepatic circulation of bile salts promotes the excretion of lipophilic mol-
ecules via the bile into the feces (e.g. cholesterol and bilirubin) and is critically im-
portant for cholesterol homeostasis in the body. The dietary fat intake in infants is 
relatively high compared to the dietary fat intake in adults, whereas their bile salt pool 
size is lower (33). Efficient absorption of dietary fat is essential for optimal growth 
and development during infancy. 
Human milk is the gold standard in infant feeding. One of the beneficial qualities of 
human milk involves the more efficient absorption of dietary fat compared to that 
from formula (34). Interestingly, the bile salt pool is larger in premature infants fed 
human milk compared to formula, but it has not been clarified whether this contrib-
utes to the mechanism underlying the more efficient fat absorption (34). Previously, 
we reported that the maturation of fat absorption in human neonates is functionally 
related to an increased capacity to absorb long chain fatty acids from the intestine, 
possibly due to developmental changes in bile salt composition and bile salt pool 
(28).
Prebiotics are non-digestible food ingredients that stimulate the growth and activity 
of specific bacteria in the colon (i.e. bifidibacteria and lactobacilli) (14). Oligosac-
charides are a major constituent of human milk and have been demonstrated to in-
crease the proportion of bifidobacteria and lactobacilli in the infant’s colon (4, 9). 
The prebiotic galactooligosaccharides (GOS) and fructooligosaccharides (FOS) are 
known to increase the number of bifidobacteria and lactobacilli in the gut in both 
human and animal studies (3, 26, 32). Previous studies in rats, using the prebiotic 
substrate FOS, have shown an increase in the amount of intestinal bifidobacteria and 
lactobacillus (25, 31).
It is not known whether oligosaccharides, the prebiotic constituent of human milk, 
influence the bile salt metabolism and thereby play a role in the more efficient fat 
absorption of breast milk. Interactions between intestinal flora and bile salts are well 
known. The bacterial metabolism of bile salts in the intestinal lumen can involve 
deconjugation and dehydroxylation, converting primary bile salts such as cholate 
and chenodeoxycholate, into secondary bile salts (i.e. deoxycholate and lithocholate). 
Bacterial metabolism of bile salts is partly responsible for the fractional turnover rate 
of primary bile salts i.e. the portion of the pool that is newly synthesized per day. 
Bacterial metabolism may also influence the physiological activity of bile salts, since 
secondary bile salts are more hydrophobic than primary bile salts and therefore have 
a greater capacity to interact with dietary fat. 
Recently we developed a method to quantify cholate fluxes in the enterohepatic circu-
lation of experimental animals (19). This method is based on a stable isotope dilution 
methodology used in humans that was successfully downscaled to allow measure-
ment of cholate fluxes in experimental animals (19). The enterohepatic circulation of 
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bile salts can be quantitatively characterized by specific kinetic parameters: the pool 
size (the amount of bile salts in the body), the FTR (the fraction of the pool that is 
newly synthesized each day), the synthesis rate, and, finally, the cycling time (the time 
it takes the cholate pool to undergo one full cycle in the enterohepatic circulation). In 
the present study, we determined the effect of dietary prebiotic oligosaccharides on 
the enterohepatic circulation of cholate, the major primary bile salt in rats.
MATERIALS AND METHODS
animals and materials
Six week old male rats (Harlan Laboratories, Zeist, The Netherlands) were housed in a 
light- and temperature- controlled facility, with free access to tap water and to either 
the prebiotic diet or the control diet. Experimental protocols were approved by the 
Ethical Committee for Animal Experiments, Faculty of Medical Sciences (University 
Medical Center Groningen, The Netherlands). 2, 2, 4, 4 -Tetradeuterated cholic acid 
([2H
4
]-CA; isotopic purity, 98%) was obtained from Isotec (Miamisburg, OH). All 
other chemicals and solvents used were of the highest purity commercially available. 
Animals received semi-purified AIN-93-based diets pressed into pellets (Research 
Diet Services, Wijk bij Duurstede, The Netherlands). In the prebiotic diet, the supple-
mented oligosaccharides were exchanged for the same amount of carbohydrates. The 
experimental diet was supplemented with GOS, lcFOS and AOS, in a dose of 7.65, 
0.85 and 0.90 wt%, respectively (Table 1).
Table 1.  composition of the prebiotic diet and the control diet





dextrinized cornstarch 132.0 65.9
sucrose 100.0 72.3
cellulose 50.0 50.0
pure carbohydrate mix numico* - 93.8
soybean oil 70.0 70.0
*85 g galactooligosaccharides (Gos), long-chain fructooligosacharides (lcFos) 
(9:1), and 8.8 g acidified oligosaccharides (aos).




Male Wistar rats (body weight 253 ± 11 g) were fed the control diet for three weeks 
as a run in, after which they were randomly assigned to the prebiotic or the control 
diet for another 3 wk (n=8 per group). Body weight was measured weekly; food 
intake and fecal production were measured during 72 h in the third week after ran-
domisation. Three weeks after randomisation, relevant parameters of synthesis and 
enterohepatic circulation of cholate were determined using the previously mentioned 
stable isotope dilution technique (19). In short, 3.0 mg of 2H
4
-CA in a solution of 
0.5% NaHCO
3
 in phosphate-buffered saline was slowly injected via the penile vein 
during isoflurane anesthesia. Blood samples were taken before injection and at 12, 
24, 36, 48, 60, and 72 h after injection. Blood samples (300 μl) were collected 
by tailbleeding under isoflurane anesthesia. Blood was collected in EDTA tubes and 
centrifuged to obtain plasma. After centrifugion (3,000 rpm for 10 min at 4˚C), 
plasma was stored at -20°C until analysis. At the last day of the experiment, rats were 
equipped with a catheter in the bile duct, and bile was collected for 30 min. Animals 
were euthanized by heart puncture, after which the liver and colon contents were 
collected and stored at -80°C until analysis.
analytical procedures
Plasma alanine transaminase, aspartate transaminase, alkaline phosphatase, cholesterol 
and triglyceride concentrations were determined by routine laboratory techniques. 
Concentrations of biliary cholesterol and phospholipids were measured as described 
(13, 16), as were bile salt concentrations in feces and in bile (24). Fecal bile salt 
composition and fecal neutral sterols were analyzed as follows: 50 mg of dried feces 
was boiled in 1 ml alkaline methanol (1M NaOH / Methanol, 1:3 vol/vol) at 80oC 
for 2 h after addition of 50 nmol 5α-Cholestane and 14 nmol 7α,12α-dihydroxy-
5β-cholanic acid as internal standard for neutral sterols and bile salts, respectively. 
After cooling down to room temperature, neutral sterols were extracted by using 3 x 
3 ml of petroleum ether, boiling range 60-80 o C. The residual sample was diluted 1: 9 
with distilled water. A sample (100 μl) of the solution was subjected to an enzymatic 
total bile salt measurement (24). The residual sample was used for bile salt isolation 
by reversed phase solid phase (C18) extraction (24, 30). The eluate was evaporated to 
dryness, and bile salts were derivatized to the methyl ester–trimethylsilyl derivatives 
for gas chromatography analysis. The extracted neutral sterols were derivatized to the 
trimethylsilyl derivatives applying the same procedure that was used for bile salts. Bile 
salt composition of prepared bile samples, fecal samples and neutral sterol composition 
of prepared feces samples were determined by capillary gas chromatography on an 
Agilent gas chromatograph (HP 6890) equipped with a 25 m x 0.25 mm CP-Sil-19 
fused silica column (Varian, Middelburg, The Netherlands) and a flame ionization 
detector. The conditions were as follows: Injector temperature 280 ºC; pressure 
16.0 psi; column flow constant at 0.8 ml/min; oven temperature program: 240 ºC 
( 4 min), 10 ºC/ min to 280 ºC ( 27 min); detector temperature 300 ºC. Hepatic 
concentrations of triglycerides and cholesterol were measured using commercial kits 
(Wako Chemicals, Neuss, Germany and Roche Diagnostics, Mannheim, Germany ) 
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after livers were homogenized. Pooled plasma samples were used for lipoprotein 
separation by fast-protein liquid chromatography (FPLC) on a Superose 6B 10/30 
column (Amersham Biosciences). The concentration of triglycerides in the various 
fractions was determined using a commercial kit (Wako Chemicals).
Gas-liquid chromatography electron capture negative chemical ionisation 
mass spectrometry and calculations
Plasma samples were prepared for isotopic analysis of bile salts by gas chromatog-
raphy mass spectrometry (GC-MS) as described (19; 27). Analyses were performed 
at the pentafluoro-TMS derivative using a Finnigan SSQ7000 Quadrupole GC-MS 
(Finnigan MAT, San José, CA). GC separation was performed on a 15 m x 0.25 mm 
column, 0.25 μm film thickness (AT-5MS, Alltech Associates, Deerfield, IL). The area 
ratio M4/M0 is calculated after computerized integration of peak areas of M4 CA 
and M0 CA in the mass chromatograms for m/z 627.3 and 623.3, by using LCQuan 
software (Finnigan MAT). Enrichment is defined as the increase of M4/M0 after 
administration of [2H
4
]-CA and expressed as the natural logarithm of the atom% ex-
cess (ln APE) value. The decay of ln APE over time was described by linear regression 
analysis. From this linear decay curve the FTR and pool size of CA were calculated. 
The FTR (day-1) equals the slope of the regression line. The pool size (μmol/100 g 
body wt) is determined according to the formula: Pool size = (D x b x 100/ea) –D, 
where D is the administered amount of label, b is the isotopic purity, and a is the 
intercept on the y axis of the ln APE-vs.-time curve. The CA synthesis rate (μmol·100 g 
body wt ˉ1·day ˉ1) is determined by multiplying pool size and FTR.
enterohepatic cycling time
The cycling time of the enterohepatic circulation is the time it takes for a bile salt to 
undergo one full cycle. The cycling time for cholate can be estimated by dividing the 
cholate pool size by the biliary secretion rate of cholate (which was calculated using 
bile salt composition in bile and bile flow rates after bile canulation). The fraction of 
cholate lost per cycle was calculated by dividing fractional cholate synthesis rate by 
cholate cycling frequency.
Fecal flora composition
Frozen fecal or colon samples were thawed by adding 1 ml of MilliQ water and heating 
at 90 °C. The suspensions were subsequently homogenized and frozen overnight at 
−20 °C. The homogenized samples were thawed at room temperature, followed by 
DNA isolation using the NucliSense Isolation Extraction Kit (BioMerieux, Boxtel, The 
Netherlands). For the relative quantification of the genera Bifidobacterium and Lactobacillus 
in relation to the total bacterial load, a duplex 5′ nuclease quantitative real-time PCR 
assay was used (15).
Briefly, different primers and probes for the genus Bifidobacterium or Lactobacillus in 
combination with primers and probes for total bacterial were used in a temperature 
profile consisting of 2 min at 50 °C, 10 min at 95 °C, followed by 45 cycles of 15 
s at 95 °C and 60 °C for 1 min, run on ABI Prism 7700 PCR equipment (Applied 
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Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). The relative amounts of the 
genus Bifidobacterium or Lactobacillus in the samples were calculated with respect to the 
total bacterial load according to Liu et al. (23), and expressed in percentages. All 
samples were analyzed in triplicate.
Statistics
Values represent means ± SD for the indicated number of animals per group. 
Differences between the two groups were determined by Student’s t-test for normally 
distributed values, and Mann-Whitney exact 2-tailed U-test was used for nonnormally 
distributed data. P < 0.05 was considered significant. Analysis was performed using 
SPSS 12.0 for Windows software (SPSS, Chicago, IL).
RESULTS
animal characteristics 
Animals fed the prebiotic diet or the control diet, were comparable in body weight, 
growth, fecal production and food intake (Table 2). The prebiotic diet significantly el-
evated serum lathosterol, an intermediate in the cholesterol synthesis pathway, where-
as plasma concentrations of cholesterol, triglycerides, alanine transaminase, aspartate 
transaminase and alkaline phosphatase were not altered upon treatment (Table 2). 
Table 2. animal characteristics, plasma and hepatic parameters of lipid metabolism and liver function 
after feeding rats a prebiotic or a control diet
Control diet Prebiotic diet
Animal characteristics
body weight (g) 252 ± 12 254 ± 11
body weight at termination (g)
Feces (wet ) (g/day/100 g body weight)
Food intake (g/24 h)
456 ± 35
 0.4 ± 0.1
27.9 ± 1.7 
  476 ± 28
  0.4 ± 0.1








 3.0 ± 0.2
14.3 ± 5.4
 5.4 ± 0.7
 14.8 ± 1.7
     3.1 ± 0.2
  14.7 ± 5.6
  5.7 ± 1.7
Plasma parameters
alanine transaminase (units/l)   46 ± 10  45 ± 7
aspartate transaminase (units/l)  153 ± 75   155 ± 49
alkaline phosphatase (units/l)   6 ± 7   2 ± 1
cholesterol (mmol/l)    1.8 ± 0.3     1.9 ± 0.5
triglycerides (mmol/l)    1.4 ± 0.5    1.9 ± 1.0
lathosterol (µmol/l)  0.7 ± 0.1      1.3 ± 0.5*
all values are expressed as means ± standard deviation. * p < 0.05; n = 8 per group.
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effect of prebiotic treatment on the composition of intestinal flora
Figure 1 shows that the prebiotic diet had a prominent bifidogenic effect. After 
3 wk the relative numbers of bifidobacteria and of lactobacilli were significantly 
higher in colon content and in feces in rats fed the prebiotic diet compared with 
controls. The proportion of lactobacilli increased 344% (P < 0.01) in colon content 
and 139% (P < 0.05) in feces compared with rats on control diet (Fig. 1). 
Prebiotic treatment also increased the contribution of bifidobacteria 366% (P < 0.01) 
in colon content and 282% (P < 0.01) in feces compared with the control group 
(Fig. 1). The prebiotic diet significantly lowered pH in both colon content and feces 
with 1.0 and 0.5 pH point, respectively (Fig.1).
effect of prebiotic intervention on parameters of the enterohepatic 
circulation of bile salts
Bile flow and biliary secretion rates of bile salts, phospholipids and cholesterol were 
similar between the groups (Fig. 2), as were biliary bile salt composition (Fig. 3), fecal 




































































Figure 1. effect of prebiotic treatment (solid bars) on percentage of total bacterial load of 
bifidobacteria (A) and lactobacilli (B) in feces and colon content compared with control rats (open 
bars). effect of prebiotic treatment on pH in feces and colon content (C). prebiotic-treated rats are 
significantly different from controls. data are expressed in means ± sd of n = 8 per group; * P < 0.05; 
** P < 0.01. 











































































































Figure 2. effect of prebiotic diet (solid bars) on bile flow (A), total bile salts (B), phospholipids (C), 
and cholesterol (D) in bile compared with the control rats (open bars). data are expressed in means 
± sd of n = 7 or 8 per group. no significant differences between prebiotic-treated rats compared to 

































Figure 3. effect of prebiotic treatment (solid bars) on biliary bile salt composition compared with 
control rats (open bars). data are expressed in means ± sd of n = 7 or 8 per group. no significant 
differences between prebiotic-treated rats compared with controls. c, cholate; dc, deoxycholate; 




Table 3. pool size, fractional turnover rate and synthesis rates of cholate
Prebiotic diet Control diet
Fractional turnover rate 
(day -1)
0.28 ± 0.04 0.26 ± 0.07
pool size 
(µmol/100 g body wt)
8.11 ± 1.82 8.80 ± 2.57
synthesis rate 
(µmol/100 g /day)
2.25 ± 0.55 2.23 ± 0.72
values are obtained by [2H4]-ca isotope enrichment measurements in plasma of rats fed the 
prebiotic diet or the control diet, as detailed in materials and methods. values are expressed 
in means ± sd (n = 7-8 rats per group). no significant differences between prebiotic treated rats 
































































Figure 4. effect of prebiotic treatment on fecal bile salt excretion (A) and fecal neutral sterol excre-
tion (B). prebiotic diet (solid bars), control diet (open bars). values are expressed in means ± sd, and 
n = 8 per group. no significant differences between prebiotic-treated animals compared with controls 
in any of the parameters. α-m, α-muricholate; dc, deoxycholate; β-m, β-muricholate; c, cholate; 
Hdc, hyodeoxycholate. copr, coprostanol; epicopr, epicoprostonol; chol, cholesterol; dih-chol, 
dihydrocholesterol.  

















B. Control diet 
Figure 5. cholate synthesis rate, pool size and fecal excretion in rats fed a prebiotic diet (A) or a 
control diet (B); (n=7 or 8 per group). the cycling time of the enterohepatic circulation is the time 
it takes for a bile salt to undergo one full cycle. the cycling time for cholate can be estimated by 
dividing the cholate pool size by the biliary secretion rate of cholate. the biliary secretion rate 
of cholate was similar in both groups (data not shown). the fraction of cholate lost per cycle was 
calculated by dividing fractional cholate synthesis rate by cholate cycling frequency. no significant 
differences between prebiotic treated rats compared to controls in any of the parameters.
Figure 6. distribution of triglycerides in plasma lipoprotein fractions in prebiotic treated rats (closed 
symbols) and controls (open symbols). lipoproteins were separated by using fast protein liquid 
chromatography (Fplc). plasma from all individual rats per group (n = 8 per group) was pooled and 
subjected to gel filtration using superose 6 columns. triglyceride concentration in each fraction 
was measured as described in Analytical procedures. the amount of triglycerides in the separated 
























did not affect the enterohepatic circulation of bile salts. Kinetic parameters of cholate, 
the main bile salt in rodents, were not significantly altered by the prebiotic diet. 
Cholate synthesis rate, pool size and FTR, as well as fecal excretion, were similar in 
both groups (Table 3 and Fig. 5). 
effect of prebiotic treatment on hepatic and plasma lipids
The prebiotic treatment did not affect hepatic and plasma concentrations of cholesterol 
and triglycerides (Table 2). Upon FPLC separation of plasma lipoproteins, the 
distribution of triglycerides in the different fractions was comparable in prebiotic-
treated rats and controls (Fig. 6). 
DISCUSSION
We investigated whether prebiotic treatment and subsequent alteration of the intes-
tinal bacterial flora affects the enterohepatic circulation and composition of bile salts 
in rats. The results show that prebiotic treatment significantly increased the relative 
contributions of both lactobacilli and bifidobacteria in the colon and the feces of rats. 
Furthermore, pH in both colon and feces significantly decreased after feeding rats a 
prebiotic diet. This prebiotic effect, however, did not significantly affect bile flow or 
bile salt composition, or the synthesis and enterohepatic circulation of cholate.
The liver parenchymal cells synthesize the primary bile salts cholate and chenode-
oxycholate. Primary bile salts are conjugated before their secretion into bile (in rats 
predominantly to taurine). Upon entering the proximal small intestine, conjugated 
bile salts stimulate the emulsification and absorption of dietary fat. Conjugated bile 
salts are efficiently reabsorbed in the terminal ileum, mediated by the apical sodium-
dependent bile salt transporter (Asbt) and the basolateral transporter Ost α/β. Pri-
mary bile salts that escape absorption in the terminal ileum may be deconjugated by 
the bacterial flora in the colon and then undergo (7-alpha-) dehydroxylation result-
ing in the formation of secondary bile salts such as deoxycholate and lithocholate. 
Various intestinal bacterial species, including lactobacilli and bifidobacteria, have the 
capacity to metabolize bile salts (10). The secondary bile salts are partly reabsorbed 
by passive diffusion or are lost via the feces. Intestinal reabsorption of secondary bile 
salts, dependent on passive diffusion, is less efficient than the Asbt-mediated transport 
of primary bile salts.
Under steady-state conditions, fecal bile salt loss is compensated by synthesis of pri-
mary bile salts in the liver. In theory, modification of intestinal bacterial flora and 
subsequent altered distribution of bile salts between primary and secondary type 
could influence intestinal absorption and fecal excretion of bile salts and therefore 
affect kinetic parameters of bile salt homeostasis. In preterm infants fed human milk, 
the bile salt pool size is larger compared with formula-fed infants, indicating that 
dietary factors affect the pool size (34). Also, fecal bile salt concentrations are higher 
in infants fed human milk and contain a smaller fraction of secondary bile salts, com-
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pared with those fed formula (16). Breast-fed infants have an intestinal bacterial flora 
which is characterized by relatively high amounts of bifidobacteria and lactobacilli 
(4, 17, 20, 29). Because of the fermenting ability of these bacteria, a lower stool pH 
is found in infants fed human milk compared with formula-fed infants. The prebiotic 
capacity of human milk induces a different intestinal environment, which could, in 
theory, alter the enterohepatic circulation of bile salts. Our present data show that a 
prebiotic treatment altered the intestinal bacterial flora in adult rats, indicated by a 
significant induction of colonic and fecal bifidobacteria and lactobacilli, and a sig-
nificant decrease in fecal pH. Interestingly, however, the prebiotic diet did not affect 
either the bile salt composition or the kinetic parameters of the enterohepatic bile salt 
circulation (Fig. 5). 
Theoretically, these observations could be due to a different response to a prebiotic 
diet in rats compared with other species. The present prebiotic treatment resulted in 
lactobacilli, accounting for 2.0% and 1.8% of total bacterial load in colon and feces, 
respectively. The same diet (AIN-93G) supplemented with 10 wt% GOS/lcFOS (ratio 
9:1) resulted in 7.5 % lactobacilli in feces of mice (32). Haarman et al. (15) found 
fecal flora to contain 4.4 % lactobacilli in infants receiving a formula supplemented 
with 0.8 g/100 ml GOS/lcFOS (ratio 9:1) for 6 wk, similar to values observed in 
breast-fed infants. Despite the still limited absolute contribution of lactobacilli, the 
deceased colonic and fecal pH indicates that a physiological respons is achieved.
However, the bacterial flora of infants fed human milk contains > 60 % bifidobacteria 
within 1 wk after birth (17). The addition of a GOS/FOS mixture to infant formula 
resulted in an increase of fecal bifidobacteria of almost 60 % in healthy infants (20). 
Vos et al. (33) used an identical prebiotic diet (10 wt% GOS/lc-FOS; ratio 9:1) in a 
murine model, resulting in 40% bifidobacteria of total bacterial load in fecal sam-
ples. Surprisingly, the present study showed a contribution of bifidobacteria of 1.3% 
and 1.5% in feces and colon content, respectively, after prebiotic treatment. Thus, 
although the presently used diet resulted in an increase of lactobacillus in the same 
range as mice and human, and a significant decrease in fecal and colonic pH, the less 
pronounced bifidogenic response could theoretically contribute to the observed lack 
of effect on the enterohepatic circulation of bile salts. 
It should be realized that the situation studied in the present rat model differs in 
several aspects from the physiology in human infants. Besides the less pronounced 
prebiotic respons, it cannot be excluded that the absence of a gallbladder in rats 
influences the dynamics of the enterohepatic circulation of bile salts. Furthermore, 
immaturity of intestinal absorption of nutrients (28) and bile salts (6) intervene with 
the enterohepatic circulation of bile salts, which may render the dynamics of bile salt 
metabolism in human infants not completely comparable to the presently studied rat 
model. Finally, only in rats, the primary bile salt chenodeoxycholate in rats is further 
metabolized to α-muricholic acid and β-muricholic acid, rendering the bile salt pool 
more hydrophilic compared with the human situation. In the present experiment, 
however, the amount of muricholic bile salts measured in bile did not exceed 25%. 
Nevertheless we are aware of the possibility that one or more of the aforementioned 
differences may limit the extrapolation of the present results to the human situation. 
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Besides the addressed differences in bile salt physiology between human infants and 
the presently used rat model, human milk contains high concentrations of cholesterol 
(2.6-3.9 mmol/L) compared with formulas (0.3-0.9 mmol/L) (5). The colonic flora 
of human infants develops its dehydroxylating capacity over the first months of life 
(2), whereas in the adult rat the dehydroxylating bacteria are well established. It is 
tempting to speculate that the larger bile salt pool size found in breast-fed infants 
could be related to the substantially higher dietary intake of cholesterol and not, 
based on our present observations, on differences in dietary oligosaccharides. 
Enhanced conjugation of bile salts by bile hydrolase-producing bacteria such as lac-
tobacilli could, in theory, be expected to increase the amount of deconjugated bile 
salts and the subsequent fecal excretion hereof. In the present study, both amount 
and composition of fecal bile salts were unaffected upon prebiotic treatment. We 
hypothesize that this can be due to the relative low contribution of lactobacillus and 
bifidobacteria to the total intestinal deconjugating capacity. Bile salt hydrolase is apart 
from lactobacillus and bifidobacteria, also detected in other bacterial species (12). 
Furthermore, efficient passive absorption of deconjugated bile salts may have masked 
a deconjugating enhancing effect, of prebiotic treatment. 
The presently applied methodology allowed determination of bile salt kinetic param-
eters in a physiologically uncompromised animal model. The parameters of cholate 
kinetics determined in this experiment were in line with previous experiments per-
formed in rats using the same method (19). Under steady-state conditions, the bile 
salt pool size is regulated by hepatic de novo synthesis of bile salts and by the efficien-
cy by which bile salts are reabsorbed in the intestine. Under steady-state conditions, 
the amount lost via the feces is equal to the amount of bile salts newly synthesized by 
the liver. A difference neither in cholate synthesis rate nor in fecal bile salt excretion 
was observed, indicating that prebiotic treatment does not affect the two important 
rate-limiting parameters of the enterohepatic circulation. We also observed that the 
fecal excretion of chenodeoxycholate-derived metabolites (muricholate, hyodeoxy-
cholate) was not altered either, suggesting no effect of prebiotic treatment on the 
synthesis of the other primary bile salt, chenodeoxycholate. 
Apart from an important role in absorption of dietary lipids, bile salts are critically 
involved in cholesterol homeostasis in the body. Prebiotic substances are suggested 
to have a plasma lipid-lowering effect in both animal and human studies. Serum 
cholesterol concentrations in bottle-fed infants decreased as the number of lactoba-
cilli in their stools increased (18). Possible mechanisms could be modulation of the 
intestinal bacterial flora with production of short-chain fatty acids inhibiting hepatic 
fatty acid or cholesterol synthesis or alteration of the bacterial bile acid deconjugat-
ing capacity and a subsequent altered fecal bile salt excretion (8). Studies in rats have 
consistently shown a decrease in plasma triglycerides after a diet supplemented with 
inulin and oligofructose (reviewed in Ref. 7). Data on plasma cholesterol, however, 
are less straightforward. A 10 wt% oligofructose supplemented diet decreased serum 
cholesterol concentrations in rats in one study (11), but the addition of oligofructose 
to the diet of lean rats did not induce a decrease in plasma cholesterol levels in an-
other study (21). Human studies investigating the effect of oligofructans on lipid me-
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tabolism have shown variable results (reviewed in Ref. 8). Our prebiotic diet did not 
significantly affect plasma concentrations of cholesterol in rats, whereas it increased 
the serum lathosterol concentration. Lathosterol is an intermediate in the cholesterol 
synthesis pathway, which could suggest that cholesterol synthesis was enhanced dur-
ing prebiotic treatment. However, cholesterol synthesis was not determined in this 
experiment, and no other indications of increased cholesterol synthesis were ob-
tained. For example, the hepatic mRNA expression of HMG-CoA reductase, encoding 
for the rate limiting enzyme of cholesterol synthesis, was not upregulated by prebiot-
ic treatment (data not shown). The presently used diet did not affect serum triglycer-
ides or hepatic triglycerides. Also, the amount of triglycerides in the VLDL fraction of 
lipoproteins was comparable in prebiotic-treated and control rats, indicating that the 
present treatment did not affect hepatic VLDL composition or triglyceride distribution 
over the various plasma lipoproteins (Figure 6). Rat studies on lipid metabolism or 
bile salt metabolism using diets supplemented with the presently used GOS/lcFOS, 
have, to the best of our knowledge, not been performed. In accordance with the pres-
ent results, a study recently performed in human infants showed unaffected plasma 
levels of cholesterol and of triglycerides in infants fed a formula supplemented with 
identical prebiotic substances in the same ratio used in the present study (1).
In summary, we conclude that feeding rats a prebiotic diet induces modification of 
the intestinal flora, and decreases the intestinal pH in the colon and the feces. How-
ever, the prebiotic diet does not influence the metabolism of bile salts in rats. The 
present data in rats do not support the hypothesis that prebiotics naturally present in 
human milk contribute to a larger bile salt pool size or altered pool kinetics. 
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Epidemiological studies have indicated that nutrition during the fetal and/or the neo-
natal period affects adult health. Over the last decades, the different concepts regard-
ing the relationship between early events and health in adulthood have emerged into 
the predictive adaptive response hypothesis as postulated by Gluckman et al (1). This 
hypothesis defines that, based on the prenatal environment, the fetus reacts to its ex-
pected postnatal environment i.e. if the prenatal environment of the fetus “predicts” 
a nutritionally poor postnatal environment, the fetus adapts to a developmental path 
appropriate for a lower postnatal nutritional supply (2). These adaptations are ap-
propriate if the expected postnatal environment is in accordance with the actual one. 
Mismatch between the expected and the actual environment, however, is suggested to 
be a major determinant in the development of (features of) the metabolic syndrome. 
The metabolic syndrome is a cluster of metabolic and cardiovascular risk factors 
including insulin resistance, diabetes, hypertension, obesity, and dyslipidemia (3). 
Dyslipidemia (elevated triglycerides and LDL-cholesterol) contributes to the develop-
ment of diabetes and of non-alcoholic fatty liver disease (NAFLD) and is, both direct 
and indirect, a risk factor for atherosclerosis. Epidemiological studies in humans and 
studies in several animal models have shown effects of early nutritional conditions on 
lipid metabolism in adulthood. 
The mechanism behind the relation between fetal events and adult disease has re-
mained unclear to a large extend. Insight in the mechanism behind metabolic pro-
gramming represents a promising area in which preventive (nutritional) strategies 
could be developed to maintain or improve future health. In this thesis we investi-
gated the effects of different fetal and neonatal nutritional conditions on lipid and bile 
acid metabolism in rodents and in human infants using stable isotope techniques. 
Protein restriction during gestation in mice 
Intrauterine growth restriction has been associated with an increased risk to develop 
features of the metabolic syndrome in adulthood (1, 4-13); a phenomenon termed 
“metabolic programming”. To clarify mechanisms behind metabolic programming, 
different animal models have been developed (14, 15).  A well-studied rodent model to 
investigate programming effects of intrauterine growth restriction is maternal dietary 
protein restriction during gestation (or fetal protein restriction). The purpose of this 
model is to mimic intrauterine malnutrition. Maternal protein restriction during 
gestation is most frequently studied in rats in which the model induced disordered 
regulation of lipid metabolism (16), high blood pressure (17, 18) and obesity and 
insulin resistance (19) in the adult offspring. Fewer protein restricted dietary studies 
have been performed in mice. Establishing the same model in mice, however, expands 
the possibilities of the model by allowing investigating the metabolic effects of 
intrauterine growth restriction in different genetically modified mice (for example, 
knock-out or transgenic). 
A proposed mechanism behind metabolic programming is that of epigenetic modi-




the underlying DNA sequence. A widely studied example of epigenetic modification 
is that of DNA methylation which causes suppression of gene expression without al-
tering the sequence of the silenced genes. Previous studies in mice performed in our 
laboratory showed that maternal gestational protein restriction increased the hepatic 
DNA methylation status of LXR (a key regulator of cholesterol and fatty acid metabo-
lism) in the fetal offspring. Subsequently, the mRNA expression of LXR and its target 
genes involved in fatty acid and cholesterol metabolism was lowered (20). In this 
thesis, we tested if these epigenetic changes with corresponding alterations of mRNA 
expression of LXR and its target genes would translate into effect on actual fluxes in 
lipid metabolism. Our data as described in chapter 3 clearly showed that the previ-
ously described effect of fetal protein restriction on fetal mRNA expression of genes 
involved in lipid metabolism was not translated into alterations in fetal fatty acid 
synthesis or in maternal-fetal cholesterol transport. This underscores the notion that 
effects on mRNA expression levels are not always translated into effects on relevant 
physiological fluxes. 
In our studies, the protein restricted diet was isocaloric to the control diet, through 
the exchange of protein for glucose (+3 % w/w) and starch (low protein diet: + 
6% w/w) compared to the control diet. We realize that a role of excess maternal 
carbohydrate intake during gestation cannot be excluded in effects of the protein 
restriction model. In our studies in mice, fetal protein restriction did not actually 
induce fetal growth restriction. Studies by others have shown that protein restriction 
during gestation affected fetal growth in rats in an inconsistent manner, varying from 
a decrease (21, 22), to no effect on fetal birth weight (20, 23). A study by Langley-
Evans even described increased fetal birth weight after fetal protein restriction in rats 
(24). 
Previous studies in mice performed in our laboratory using the same model i.e., ges-
tational dietary protein restriction without inducing fetal growth restriction, showed 
that fetal protein restriction altered DNA methylation of LXR in fetal livers and low-
ered insulin sensitivity in the adult offspring (20). We therefore consider the model 
to be relevant to study metabolic programming despite the absence of fetal growth 
restriction.  
Studies by others in mice showed that forced catch-up growth (generated by the re-
duction of littersize) after fetal protein restriction did induce features of the metabolic 
syndrome in adulthood (21). Fetal protein restriction did not exert short term effects 
on lipid metabolism in our study as described in chapter 3. We cannot exclude, how-
ever, that the earlier described effects of gestational protein restriction on fetal LXR 
methylation and gene expression, can modify lipid metabolism in an older animal 
or, according to the predictive adaptive response theory, after a second hit such as 
aggravated catch-up growth. The effect of forced catch-up growth of the offspring 
was not studied in the present thesis. It would be interesting to study the effect of 
an early postnatal overfeeding model (e.g. by reducing litter size during lactation) in 
the offspring of protein restricted mice on physiological relevant lipid fluxes such as 
cholesterol and fatty acid synthesis. 
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Intrauterine growth restriction in human infants 
Intrauterine growth restriction has been related to adult dyslipidemia in humans (2, 
7, 8, 25). Already in the neonatal period, infants that are small-for-gestational age 
(SGA) have higher plasma concentrations of total cholesterol, low-density cholesterol 
and triglycerides compared to normal weight infants (26).
It is known that infants fed human milk (containing a significantly higher amount of 
cholesterol compared to formula milk) downregulate their endogenous cholesterol 
synthesis (27). Breastfeeding is associated with lower mean total cholesterol and low-
density cholesterol levels in adulthood, suggesting that breastfeeding may have long-
term benefits for cardiovascular health, possibly by altering the metabolic set point 
for cholesterol synthesis (28). A study in which premature infants were randomly 
assigned to either human milk or formula feeding in their early postnatal life, showed 
a more favorable lipid profile in adolescence in the infants that had received human 
milk compared to the control group assigned to formula milk (29). According to 
the predictive adaptive response hypothesis we tested the hypothesis that a fetus 
subjected to a decreased placental nutrient supply would increase its cholesterol and /
or triglyceride synthesis rate and thereby alter its metabolic set point. In chapter 4, we 
investigated the influence of intrauterine growth restriction on the de novo synthesis of 
cholesterol and on de novo lipogenesis in preterm born SGA and AGA infants as model 
for the third trimester of gestation. We showed, using stable isotope methodologies, 
that intrauterine growth restriction did not influence cholesterol synthesis rates. 
Hepatic de novo lipogenesis (DNL) is the process of conversion of acetyl-CoA into 
fatty acids. After subsequent esterification of fatty acids to glycerol, triglycerides can be 
released from the liver in the form of very-low-density lipoproteins (VLDL). Hepatic 
DNL is a quantitively minor pathway of total fat accretion in adults on a Western type 
diet. During gestation, the human fetus accumulates the majority of its fat during the 
third trimester of gestation. Thus, it would seem reasonable to assume that DNL is 
increased in premature neonates, to compensate for the loss of placental transfer of 
fatty acids particularly if preterm infants are born SGA. We hypothesized that in the 
SGA fetus, the hepatic DNL would be enhanced compared with the appropriate-for- 
gestational-age fetus (AGA) to compensate for the reduced fat accretion. Our study 
indeed showed that DNL was increased in the growth restricted infants compared to 
the AGA infants, but the magnitude of the effect was relatively mild. Yet, we cannot 
exclude a cumulative long term effect of a mildly increased DNL shortly after birth. It 
has been shown that infants born SGA who experience rapid early catch-up growth 
have an increased risk to develop obesity (30). Future research should thus focus 
on the effect of enteral nutrition and/or catch-up growth on the de novo synthesis of 
lipids. 
Pharmacological LXr activation during gestation in mice
The nuclear receptor LXR is a key player in the regulation of cholesterol and in the 
synthesis of lipids. LXR is proposed to be involved in maternal-fetal cholesterol 
transport. In theory, manipulation of LXR during gestation could thus affect fetal 




determined if synthetic activation of LXR in utero would affect both fetal and adult 
lipid metabolism. Administration of the well studied synthetic LXR agonists T0901317 
to pregnant females (dams) increased the expression of LXR target genes in both 
maternal and fetal liver. Short-term effects on fetal lipid metabolism were present 
in both dams and fetuses including increases in fatty acid synthesis and triglyceride 
levels. Despite these profound changes in lipid metabolism during fetal life, only mild 
effects persisted into young adulthood. A high-fat diet challenge did not induce a 
different lipid response in the young adult offspring of LXR agonist treated dams. It is 
not excluded however, that programming effects of the pharmaceutical intervention 
would appear at a later age. 
Prebiotic oligosaccharides and the enterohepatic circulation of bile salts in rats
Human milk, the gold standard in infant nutrition, contains prebiotic oligosaccha-
rides which are non-digestible food ingredients that stimulate the growth of health 
improving colonic bacteria (bifidobacteria and lactobacillus). In the last decade, in-
fant formulas are increasingly supplemented with prebiotics in order to mimic the 
physiological effects of human milk in neonates. 
Short-term effects of human milk on lipid and bile acid metabolism have been 
described: infants fed human milk have a larger bile acid pool size and a more efficient 
fat absorption (31, 32). We were interested if the enhanced fat absorption as found in 
breastfed infants could be attributed to an effect of prebiotic oligosaccharides on bile 
acid metabolism. In chapter 6 we showed in (adult) rats that dietary supplementation 
with prebiotic oligosaccharides increased the presence of colonic lactobacillus and 
bifodobacteria and decreased the colonic pH. This prebiotic effect, however, did not 
affect kinetic parameters of bile acid metabolism, such as pool size, biliary bile salt 
secretion rate and cycling time. The lack of any effect of the prebiotic effect on bile acid 
metabolism, although studied in adult animals, does not support the hypothesis that 
supplementation of formula with prebiotics positively affects bile acid metabolism in 
infants. We do realize that the results in the presently used model of adult rats may not 
be the same in the situation of human infants, but an isolated effect of the prebiotic 
oligosaccharides is nevertheless unlikely. 
CONCLUSION
The aim of the studies described in this thesis was to elucidate effects of fetal growth 
restriction and of a farmacological manipulation during gestation on lipid metabo-
lism. Administration of a synthetic LXR agonist did exert short-term changes in fetal 
lipid metabolism without significantly affecting lipid metabolism in young adult-
hood. We showed in mice that previously described epigenetic changes using the 
identical fetal protein restriction model are not translated into short-term effects on 
lipid metabolism. In preterm infants, intrauterine growth restriction did not exert 
major effects on lipid synthesis. These studies indicate that fetal undernutrition does 
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not exert overt fetal adaptations in lipid metabolism that can be discriminated with 
the currently used techniques. We speculate that the manifestations of programming 
may either be subtle, visible in different body compartments, and/or may become 
(more) prominent after other forms of dietary/environmental challenges at adult 
life. 
Stable isotope methodologies have been proven sensitive enough to delineate the 
consequences of the early environment in both rodents and in human infants. Stud-
ies investigating metabolic nutritional programming focused to a large extent on the 
health impact of under-nutrition during gestation. Under-nutrition during gestation 
and IUGR are still present in developed countries, and are more common in develop-
ing countries.  Considering the increasing incidence of obesity in Western societies 
however, it would be logical to extend the focus of research to the metabolic conse-
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A large volume of epidemiological data indicates that determinants of health and dis-
ease in adult life partly originate from environmental conditions in the fetal and early 
postnatal period. The maternal condition during gestation, the birth weight and the 
nutritional supply in the first postnatal year, can affect health in adulthood. Impaired 
nutrition of the mother during pregnancy and/or being born with a low birth weight 
is associated with an increased risk of developing chronic diseases at a later age. These 
chronic, predominantly “adult” diseases are features of the “metabolic syndrome” 
such as diabetes, hypertension, obesity and dyslipidemia. The scenario by which early 
adaptations to a (nutritional) stimulus permanently change the physiology and the 
metabolism of the organism, and continue to be expressed even in the absence of the 
stimulus that initiated them, is termed “metabolic programming”. The mechanisms 
underlying this phenomenon are largely unknown. Insight in the pathophysiologi-
cal mechanisms underlying metabolic programming could eventually allow for tar-
geted, preventive, e.g. nutritional manipulations in the early environment, thereby 
improving long-term health. In this thesis we set out to characterize and unravel the 
consequences of and the mechanisms underlying specific dietary and pharmacologi-
cal interventions during prenatal and early postnatal life on physiologically relevant 
parameters of lipid and bile acid metabolism. To position the context of our studies 
we first addressed to lipid and bile acid metabolism. 
Lipid and bile acid metabolism
It is well known that elevated plasma lipid levels (low-density cholesterol and trig-
lycerides) constitute a risk factor for the development of cardiovascular disease. Less 
familiar is the fact that lipids such as fatty acids and cholesterol are also indispen-
sible for normal growth and development, especially in the fetal period. Lipids are 
water-insoluble molecules with several essential functions in mammals. Cholesterol 
is a component of cell membranes and a precursor for steroid hormones and bile 
acids. In addition, cholesterol is needed to activate Sonic Hedgehog, a signaling pro-
tein which is essential in embryonic development. Cholesterol can enter the body 
via external supply (diet, or during fetal life placental supply) or via endogenous 
production; de novo synthesis from acetyl-CoA with the liver being the major site of 
synthesis. 
Bile acids, which are synthesized from cholesterol in the liver, are crucial for several 
physiological relevant functions of bile. Hepatobiliary bile acid secretion is the 
main driving force for generation of bile flow. As biological detergents, bile acids 
can solubilize lipids and facilitate the uptake of dietary fat and fat soluble lipids, 
thereby providing energy and structural components needed for normal growth. 
Bile acids are also essential for the disposal of excess cholesterol from the body via 
fecal secretion. Bile acids are conserved via the enterohepatic circulation implying 
that after secretion, the majority of bile acids is reabsorbed from the intestine and 
transported back to the liver via the portal circulation. The physiological relevance 
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of bile acids and lipids, such as cholesterol, is clarified by the profound health 
consequences of inborn errors in cholesterol synthesis and bile acid synthesis as 
reviewed in chapter 2. 
the effects of intrauterine malnutrition on materal-fetal cholesterol transport 
and fetal lipid synthesis in mice
As stated previously, the nutritional conditions of the mother during gestation can af-
fect the lipid metabolism of the offspring. Several animal models have been developed 
to determine the metabolic consequences of gestational under- or over-nutrition. 
Maternal low protein diet (LPD) during gestation is a well-defined model in rodents 
to study the metabolic effects of fetal under-nutrition. We used this model in mice to 
asses the effects of impaired nutrition on lipid metabolism. Previous research by oth-
ers had shown that maternal protein restriction during gestation induced decreased 
fetal hepatic mRNA expression levels of genes involved in lipid metabolism. In chap-
ter 3 we described the effects of LPD on maternal-fetal cholesterol transport and on 
fetal lipid synthesis in mice. Pregnant mice received protein restriction or a control 
diet throughout gestation. We used stable isotope techniques to determine if the pre-
viously shown changes in fetal hepatic gene expression levels were translated into 
short-term (acute) effects on physiological relevant lipid fluxes. We demonstrated 
that gestational protein restriction did neither exert immediate effects on cholesterol 
transport from dam to fetus, nor on the de novo synthesis of cholesterol or fatty acids in 
the last stage of gestation. This conclusion strongly indicated that the earlier described 
programming effects of maternal protein restriction are not mediated by short-term 
changes in maternal-fetal lipid fluxes in mice.
Intrauterine growth restriction and de novo fatty acid and cholesterol 
synthesis in preterm neonates
Since the ultimate relevance for human physiology requires studies in infants, we 
than set out to investigate the effect of intrauterine malnutrition on lipid metabolism 
in humans. Infants born prematurely can constitute a model of the last trimester of 
gestation in which the impact of environmental factors can be studied. In chapter 4 
we describe the influence of intrauterine growth restriction (as a marker for impaired 
fetal nutrition) on lipid synthesis. We used stable isotope techniques to determine 
synthesis rates of cholesterol and of fatty acids. We conclude that IUGR did not quan-
titatively affect cholesterol synthesis whereas it only relatively mildly increased DNL. 
This conclusion indicates (consistent with our results in mice) that the association 
between impaired maternal nutrition during gestation and adult dyslipidemia is not 
explained by short-term intrauterine effects on lipid synthesis. 
Fetal liver receptor activation acutely induces lipogenesis but does not affect 
plasma lipid respons to a high fat diet in mice
Not only a surplus, but also a shortage of lipids can disrupt health, especially dur-
ing the fetal period. Cholesterol and lipid metabolism is under tight control of re-
fined regulatory mechanisms in which the Liver X Receptor (LXR) is a key player. 
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Summarized, LXR is activated by oxidized cholesterol derivatives (oxysterols) after 
which LXR binds to its obligatory heterodimer, the Retinoid X-receptor (RXR) and 
transcription of target genes is initiated. Important LXR target genes are the ATP-
binding cassette (ABC) transporters that are responsible for the efflux of cholesterol 
into bile, or into high-density-lipoproteins in the bloodstream. Besides regulating 
cholesterol efflux from the cell, LXR activation induces activation of genes involved in 
lipogenesis. In the murine placenta LXR’s are expressed from day 10 of gestation (the 
second half of gestation) onwards. Furthermore, LXR is active in the fetal liver and 
can be stimulated via the dietary administration to the pregnant mice of the synthetic 
LXR agonist T0901317. We aimed to elucidate the effect of pharmacological activa-
tion of LXR in utero on fetal lipid metabolism in a mouse model. Additionally, we 
were interested if a short-term effect on lipid metabolism would be “programmed” 
into adulthood. In Chapter 5 we showed that the administration of a pharmalogical 
LXR agonist (T0901317) to pregnant mice induced immediate effects on fetal lipid 
metabolism. Fetal hepatic LXR target genes involved in lipid synthesis were upregu-
lated with subsequent increase in hepatic and plasma triglyceride levels in fetuses 
and dams. Lipogenesis, determined using a stable isotope technique, was increased 
in dams and fetuses after T0901317 treatment. Despite these profound immediate 
(fetal) effects, long term effects appeared to be rather mild. 
Prebiotic oligosaccharides and the enterohepatic circulation of bile acids
Comparable to fetal nutrition, early postnatal nutrition may affect health in a later 
stage. One of the short-term benefits of human milk compared to formula is the 
more efficient absorption of fat. Bile acids are relevant for the uptake of fat and fat-
soluble vitamins from the gastrointestinal tract, thereby facilitating normal growth. 
Interestingly, the bile acid pool size is larger in premature infants when they are fed 
human milk compared to formula. Extensive efforts have been made to improve the 
composition of infant formulas by adding ingredients that are specific for human 
milk such as prebiotic oligosaccharides. Prebiotic oligosaccharides are nondigestible 
food ingredients that stimulate the growth and activity of specific bacteria with 
supposed beneficial properties in the colon, e.g. bifidobacteria and lactobacilli. In 
chapter 6 we evaluated the effect of a prebiotic diet on relevant parameters of bile 
acid metabolism. We hypothesized that alteration of the colonic bacterial flora due to 
the prebiotic diet would affect the bile acid metabolism via bacterial deconjugation 
and/or dehydroxylation. Administration of dietary oligosaccharides to rats induced a 
significant increase in the proportion of colonic and fecal lactobacilli and bifidobacteria. 
Furthermore, the colonic and fecal pH, as a marker for the fermenting capacity of 
bifidobacteria and lactobacilli, decreased significantly. Despite the prebiotic effect, no 
effect on bile acid kinetics (pool size, synthesis rate and cycling time) was observed. 
The present study indicates that the larger pool size observed in infants fed human 
milk is not related to altered bile acid kinetics due to prebiotics naturally occurring 




The aim of the research described in this thesis was to characterize and unravel the 
role of specific dietary and pharmacological interventions during prenatal and (early) 
postnatal life on physiological relevant parameters of lipid and bile acid metabolism. 
Mimicking fetal malnutrition using protein restriction during gestation in mice did 
not affect lipid metabolism in the fetal period. Previously induced epigenetic and 
mRNA changes after using the same model were not translated into short-term (fetal) 
effects on lipid metabolism. In contrast, the administration of a synthetic LXR agonist 
to pregnant mice did affect the lipid metabolism in the fetus. However, these effects 
only mildly persisted into a later age. Intrauterine growth restriction in human infants 
did not substantially affect lipid metabolism as was demonstrated in premature new-
borns. These studies indicate that fetal malnutrition does not lead to profound fetal 
adaptations in lipid metabolism as measured with the present techniques. Our studies 
also indicate that the applied stable isotope techniques are sensitive enough to inves-
tigate the consequences of the early (nutritional) environment on lipid metabolism 
in humans and in a mouse model. Considering the increasing incidence of obesity in 
the Western world, it would be interesting to extend the focus of research in this field 





Een groot aantal epidemiologische studies laat zien dat het risico op het krijgen van 
chronische ziekten op latere leeftijd deels al vroeg in het leven bepaald wordt. De 
voedingstoestand van de moeder tijdens de zwangerschap, het geboorte gewicht en 
het voedingsaanbod in het eerste levensjaar kunnen de gezondheid op latere leeftijd 
beïnvloeden. Ondervoeding van de moeder tijdens de zwangerschap is geassocieerd 
met een verhoogde gevoeligheid voor het ontwikkelen van chronische aandoeningen 
die passen in het zogenoemde metabool syndroom. Dit is een cluster van chronische 
ziektes zoals diabetes, obesitas, hart-en vaatziekten, hypertensie en dyslipidemie (een 
verstoorde vetbalans). Het verband tussen prenatale voeding en de ontwikkeling van 
ziekten op latere leeftijd wordt “metabolic programming” genoemd. De oorzakelijke 
mechanismen die aan dit fenomeen ten grondslag liggen zijn grotendeels onbekend. 
Inzicht in die mechanismen zou uiteindelijk kunnen leiden tot het ontwikkelen van 
specifieke preventieve (voedings)interventies in het vroege leven, om de gezondheid 
op langere termijn gunstig te beïnvloeden.   
Het doel van het in dit proefschrift beschreven onderzoek was om de fysiologische 
consequenties van verschillende voedings- en farmacologische interventies in de foe-
tale en (vroege) postnatale periode op het galzouten- en vetmetabolisme te onder-
zoeken. Om de beschreven studies in context te plaatsen worden eerst het lipiden-
metabolisme (aan de hand van een belangrijk lipide, namelijk cholesterol) en het 
metabolisme van galzouten behandeld. 
Lipiden- en galzout metabolisme
Het is algemeen bekend dat dyslipidemie (verhoogde plasma concentraties van low-
density-cholesterol en triglyceriden) een risico factor is voor het ontwikkelen van 
hart-en vaatziekten. Minder bekend is het feit dat lipiden zoals vetzuren en cholesterol 
juist essentieel zijn voor normale groei en ontwikkeling, vooral in de foetale peri-
ode. Lipiden zijn niet-wateroplosbare moleculen met een aantal essentiële functies. 
Cholesterol is een bestanddeel van het celmembraan en een voorloper van steroïd-
hormonen en van galzouten. In de foetale periode is cholesterol nodig voor de nor-
male embryonale ontwikkeling. Het lichaam kan cholesterol verkrijgen via de externe 
route, uit het dieet, of in de foetale periode via de placenta. Hiernaast kan het lichaam 
zelf cholesterol aanmaken via het proces dat de novo synthese van cholesterol wordt ge-
noemd. Hierbij wordt cholesterol gesynthetiseerd uit acetyl-CoA, wat voornamelijk 
plaatsvindt in de lever. 
Galzouten, die in de lever uit cholesterol gesynthetiseerd worden zijn essentieel voor 
een aantal fysiologisch belangrijke functies van gal. Hepatobiliare uitscheiding van 
galzouten is de voornaamste drijfveer voor het ontstaan van de galstroom vanuit de 
lever. Door hun zeepachtige structuur kunnen galzouten vetten emulgeren waarmee 
ze de opname van vet en vetoplosbare vitamines uit de voeding mogelijk maken. 
Galzouten zijn daarom onmisbaar voor normale groei en ontwikkeling. Het galzout 
metabolisme speelt ook een belangrijke rol bij de uitscheiding van overtollig choles-
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terol via de feces. Galzouten worden in het lichaam “gerecycled” door middel van de 
enterohepatische kringloop. Dit houdt in dat galzouten, nadat ze hun werk in de darm 
hebben gedaan, voor het grootste deel worden gereabsorbeerd en via het portale 
bloed terug worden getransporteerd naar de lever.
De belangrijke rol van lipiden en galzouten wordt duidelijk door de ernstige gevol-
gen van aangeboren afwijkingen in de aanmaak van cholesterol en van galzouten. In 
hoofdstuk 2 worden galzout- en cholesterol metabolisme beschreven, evenals ver-
schillende aangeboren aandoeningen in de aanmaak van cholesterol en galzouten en 
hun klinische consequentie. 
De gevolgen van intra-uteriene ondervoeding op maternaal-foetaal 
cholesteroltransport en op de foetale vetsynthese in muizen
Zoals eerder vermeld kan de voedingstoestand van de moeder tijdens de zwanger-
schap van invloed zijn op de vetstofwisseling van haar nageslacht op latere leeftijd. 
Er zijn verschillende diermodellen ontworpen om de metabole consequenties van 
onder- en overvoeding tijdens de zwangerschap te bestuderen. Een welbeproefd mo-
del in knaagdieren om de gevolgen van maternale ondervoeding tijdens de zwanger-
schap te onderzoeken, is het geven van eiwitbeperking tijdens de zwangerschap. We 
gebruikten dit model in muizen om de effecten van maternale ondervoeding op de 
vetstofwisseling in de foetus te bestuderen. Eerder onderzoek waarin hetzelfde model 
gebruikt werd, toonde aan dat maternale eiwitbeperking tijdens de zwangerschap 
leidde tot verminderde expressie van mRNA van genen die betrokken zijn bij het 
lipidenmetabolisme in foetale levers. In hoofdstuk 3 onderzochten we het effect van 
deze veranderingen in genexpressie op het maternaal-foetale cholesterol transport en 
op de foetale aanmaak van cholesterol en vetzuren. Zwangere muizen werden hiertoe 
gevoed met een controle dieet of met een eiwitarm dieet tijdens de gehele zwanger-
schap. We gebruikten stabiele isotopen om maternaal-foetaal cholesterol transport en 
foetale cholesterol en vetzuursynthese te kwantificeren. Deze studie laat zien dat ma-
ternale eiwitbeperking tijdens de zwangerschap in muizen geen kwantitatieve korte 
termijn veranderingen teweegbracht in maternaal-foetaal cholesterol transport of in 
de foetale lipiden synthese in de laatste fase van de zwangerschap. 
Intra-uteriene groeivertraging en de synthese van vetzuren en cholesterol in 
premature neonaten
Het doel van dit onderzoek was om het effect van intra-uteriene groeiretardatie 
(IUGR) op de vetstofwisseling te onderzoeken. Een te vroeg geboren kind kan gezien 
worden als een model voor het laatste trimester van de zwangerschap waarin de 
gevolgen van omgevingsfactoren onderzocht kunnen worden. In hoofdstuk 4 be-
schreven we de invloed van IUGR (als een maat voor verminderde foetale voeding) 
op de synthese van cholesterol en van vetzuren. We gebruikten stabiele isotopen om 
de biosynthese van cholesterol en vetzuren te meten. We concluderen dat IUGR niet 
tot kwantitatieve veranderingen in de synthese van cholesterol leidt, terwijl de bio-
synthese van vetzuren wel, maar slechts matig verhoogd was. De uitkomsten van deze 
studie geven weer dat de associatie tussen IUGR en dyslipidemie op de volwassen 
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leeftijd niet kan worden verklaard door significante korte termijn effecten van IUGR 
op de biosynthese van vetzuren en cholesterol. 
Foetale Liver X receptor activatie stimuleert de foetale vetzuursynthese, 
maar heeft geen effect op de plasma lipiderespons op een vetrijk dieet in 
muizen
Zowel een teveel als een tekort aan lipiden beïnvloedt de gezondheid negatief. Het 
cholesterol-en vetzuur metabolisme wordt dan ook nauwgezet gereguleerd. Een be-
langrijke regulator in het cholesterol- en vetzuurmetabolisme is de liver X Receptor 
(LXR). LXR is een transcriptiefactor; een eiwit dat de transcriptie van genen regu-
leert. LXR wordt geactiveerd door oxysterolen, metabolieten van cholesterol. LXR 
bindt daarna aan zijn heterodimeer retinoid X-receptor (RXR) waarna de transcriptie 
van verschillende genen wordt aangezet. Belangrijke targetgenen van LXR zijn ATP-
binding cassette (ABC) transporters, die zorgen voor transport van cholesterol vanuit 
de cel naar gal, of naar high-density-lipoproteinen in de bloedstroom. Andere target 
genen van LXR zorgen voor het ingang zetten van de biosynthese van vetzuren.  LXR 
is aantoonbaar in de placenta van de muis vanaf dag 10, halverwege de zwanger-
schap. LXR is actief in de foetale lever en kan gestimuleerd door toedienen van een 
synthetische agonist (T0901317) aan het dieet van zwangere muizen. De experi-
menten beschreven in hoofdstuk 5 hadden als doel het effect van intra-uteriene far-
macologische activering van LXR op de foetale vetstofwisseling in een muismodel te 
onderzoeken. We waren daarbij zowel geïnteresseerd in effecten op de korte termijn, 
de foetale periode, als op de lange termijn, de volwassen leeftijd. In hoofdstuk 5 laten 
we zien dat de toediening van een farmacologische LXR activator (T0901317) aan 
zwangere muizen directe effecten op de foetale vetstofwisseling induceert. Foetale 
LXR targetgenen in de lever werden geactiveerd en er werd een toename gezien van 
de lipidensynthese. De directe (foetale) effecten persisteerden echter maar in geringe 
mate op de volwassen leeftijd. 
Prebiotische oligosacchariden  en de enterohepatische circulatie van 
galzouten in ratten
Analoog aan voeding tijdens de foetale periode, kan vroege postnatale voeding de 
gezondheid op lange termijn beïnvloeden. Een van de voordelen van moedermelk, de 
gouden standaard in babyvoeding, is de meer efficiënte vetabsorptie in vergelijking 
met kunstvoeding. Ook is de hoeveelheid galzouten aanwezig in het lichaam groter 
bij prematuren die met moedermelk gevoed worden in vergelijking met prematuren 
die kunstvoeding krijgen. Galzouten zijn essentieel in de opname van vet en vetop-
losbare vitamines uit het dieet en daardoor belangrijk voor goede groei. In een po-
ging om de voordelen van moedermelk na te bootsen in kunstvoeding, verrijkt men 
kunstvoeding vaak met componenten die in moedermelk aanwezig zijn, bijvoorbeeld 
met prebiotische oligosacchariden. Prebiotische oligosacchariden zijn onverteerbare 
voedingstoffen die de groei en activiteit van specifieke bacteriën zoals bifidobacteriën 
en lactobacillen in de darm stimuleren en op die manier de gezondheid gunstig be-
invloeden. In hoofdstuk 6 evalueren we het effect van een prebiotisch dieet op het 
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galzout metabolisme in ratten. Onze hypothese was dat verandering van de intestinale 
bacteriële flora als gevolg van het toevoegen van prebiotica, het galzout metabolisme 
via bacteriële deconjugatie en/of dehydroxylatie zou beïnvloeden. We verwachtten 
dat belangrijke parameters van het galzoutmetabolisme meer zouden lijken op die 
van borstgevoede kinderen. Toediening van oligosacchariden in het dieet van ratten 
induceerde stijging van de hoeveelheid lactobaccillen en bifidobacterien in de darm. 
Tevens was de pH (als maat voor de fermentatie capaciteit van lactobaccillen en bi-
fidobacteriën) significant lager na het toedienen van prebiotica. Ondanks dit prebio-
tisch effect, was er geen effect op het galzoutmetabolisme. Deze studie ondersteunt 
de hypothese dat de prebiotica die van nature in moedermelk voorkomen bijdragen 
aan een grotere galzouten pool niet. 
CONCLUSIE 
Het doel van het onderzoek beschreven in dit proefschrift, was om de effecten van ver-
schillende voedings- en farmacologische interventies tijdens en na de zwangerschap 
op de vetstofwisseling en op het galzout metabolisme te beschrijven. Het nabootsen 
van foetale ondervoeding met behulp van eiwitbeperking tijdens de zwangerschap 
in muizen was niet van invloed op de vetstofwisseling in de foetale periode. De toe-
diening van een synthetische LXR agonist aan zwangere muizen had wel invloed op 
het lipiden metabolisme bij de foetus. Deze effecten waren op de volwassen leeftijd 
echter nog maar in geringe mate aanwezig. Intra-uteriene groeivertraging bij kinde-
ren was niet wezenlijk van invloed op de vetstofwisseling zoals werd aangetoond bij 
premature pasgeborenen. 
Deze studies tonen aan dat foetale ondervoeding niet leidt tot significante foetale 
aanpassingen in het lipiden metabolisme. De huidige studies geven ook aan dat de 
toegepaste technieken met stabiele isotopen technieken adequaat zijn voor het on-
derzoeken van gevolgen van vroege omgevingsfactoren op het lipiden metabolisme. 
Gezien de toenemende incidentie van obesitas, zou het interessant zijn om het onder-
zoeksfocus ook te richten op de metabole gevolgen van maternale of vroeg postnatale 
overvoeding. 
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FREqUENTLy USED ABBREVIATIONS 
Abca1  ATP binding cassette, sub family A, member 1
Abcg1   ATP binding cassette, sub family G, member 1
Abcg5  ATP binding cassette, sub family G, member 5
Abcg8   ATP binding cassette, sub family G, member 8
Acc1  acetyl-Coenzyme A carboxylase 1
AGA  appropriate for gestational age
ASBT  apical sodium bile salt transporter
CA  cholate
CDCA  chenodeoxycholate
Cyp7a1  cholesterol 7α-hydroxylase
Cyp27a1  sterol-27-hydroxylase
Fasn  fatty acid synthase
HDL  high-density lipoprotein
Hmgcr  3-hydroxy-3-methylglutaryl-coenzyme A reductase
IUGR  intrauterine growth restriction
IV  intravenous
LDL  low-density lipoprotein
Lxrα  liver x receptor alpha
Lxrα  liver x receptor beta
MIDA  mass isotopomere distribution analysis
Rxr  retinoid x receptor
Scd1  steaoryl-coenzym A desaturase 1
SGA  small-for-gestational age
Srebp1c  sterol regulatory element binding protein-1c 
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